advise	coadministration of <e10> drug1 </e10> and <e22> drug2 </e22> is contraindicated .
advise	when <e11> drug1 </e11> is given concomitantly with an mao _ inhibitor ( eg , tricyclic _ antidepressants [ tcas ] , <e20> drug2 </e20> ) , a reduction in mao _ inhibition should be considered .
advise	<e11> drug1 </e11> should not be used with other <e22> drug2 </e22> ( including alcohol , barbiturates , opiates , sedatives , anesthetics , and tranquilizers ) .
advise	cyclosporine , tacrolimus and <e10> drug1 </e10> should not be used concomitantly with <e21> drug2 </e21> .
advise	nevertheless , caution is advised when <e10> drug1 </e10> is used concomitantly with <e21> drug2 </e21> .
advise	therefore , co - administration of <e10> drug1 </e10> with other drugs that may prolong the qt interval ( e , g , , atypical _ agonists , opiates , phenothiazines , <e20> drug2 </e20> , and type _ 1c _ antiarrhythmics ) should be approached with caution .
advise	at least # weeks of <e10> drug1 </e10> therapy should be continued if possible in patients who are receiving <e22> drug2 </e22> .
advise	drugs that should not be coadministered with <e11> drug1 </e11> antimigraine _ agents : phenytoin , hydroxyzine antimigraine _ agents : rasagiline antimigraine _ agents : <e20> drug2 </e20> ( e , g , , magnesium / choline _ salts ) , nefazodone
advise	dose reduction of <e10> drug1 </e10> and <e20> drug2 </e20> is not recommended when coadministered .
advise	caution should be used when <e11> drug1 </e11> is administered to patients receiving <e20> drug2 </e20> .
advise	caution should be exercised when administering <e10> drug1 </e10> with cns _ depressants such as <e21> drug2 </e21> or opioids , since the effects of drug1 may be additive or potentiated .
advise	additionally , <e11> drug1 </e11> should be given with caution to patients receiving <e20> drug2 </e20> , because drug2 binds to the same site on its own as the protease inhibitors of the bapta / dextra family , such as protease _ inhibitors ( e , g , , famotidine ) .
advise	a dose increase of <e10> drug1 </e10> to 400 mg every 8 hours is recommended when coadministered with <e20> drug2 </e20> or cimetidine .
advise	monoamine _ oxidase _ inhibitors and tricyclic _ antidepressants : <e10> drug1 </e10> should not be given with other <e22> drug2 </e22> or antidepressants .
advise	the benefits and risks of <e10> drug1 </e10> in combination with <e22> drug2 </e22> should be weighed against the potential benefits of its prothrombin time - enhancing effects .
advise	however , as with other cyp3a4 inhibitors , co - administration of <e10> drug1 </e10> with <e20> drug2 </e20> is contraindicated .
advise	dosage adjustment of <e10> drug1 </e10> may be required in patients taking <e20> drug2 </e20> .
advise	a 5 - mg <e10> drug1 </e10> dose should not be exceeded during # days of # days of # treatment with <e22> drug2 </e22> .
advise	particular caution is advised when administering <e10> drug1 </e10> to patients who are on <e22> drug2 </e22> or warfarin .
advise	caution should be exercised when <e10> drug1 </e10> is administered concomitantly with <e21> drug2 </e21> .
advise	nevertheless , caution is advised in the co - administration of <e11> drug1 </e11> with <e20> drug2 </e20> as drug2 has been shown to increase the clearance of flecainide .
advise	theophylline serum levels should be monitored regularly when <e11> drug1 </e11> is co - administered with <e20> drug2 </e20> .
advise	close supervision and careful monitoring are advised when administering <e10> drug1 </e10> to patients receiving <e22> drug2 </e22> .
advise	because prostaglandina play an important role in platelet function and blood coagulation , in addition to <e10> drug1 </e10> , other agents with a role in platelet function , such as thienopyridine _ antagonists , calcium _ channel _ blockers , and antiplatelet _ agents ( e , g , , aspirin ) , should also be given with caution in patients receiving <e20> drug1 </e20> .
advise	therefore , co - administration of <e10> drug1 </e10> and other <e20> drug2 </e20> ( eg , fluoxetine , paroxetine , desipramine , fluvoxamine ) is contraindicated .
advise	a dose adjustment of <e11> drug1 </e11> to a dose of 1 . 5 mg twice daily is recommended when used in combination with <e22> drug2 </e22> .
advise	caution should be exercised if <e10> drug1 </e10> is coadministered with <e20> drug2 </e20> .
advise	drugs that should not be coadministered with <e11> drug1 </e11> antimigraine _ agents : valsartan , phenytoin , indinavir , <e20> drug2 </e20> antimycobacterial _ agents : rifampin antimycobacterial _ agents : rifabutin antimycobacterial _ agents : macrolide _ antimycobacterial _ agents : rifabutin antimycobacterial _ agents : cisapride
advise	itraconazole plasma concentrations should be monitored closely if <e11> drug1 </e11> is administered concomitantly with <e22> drug2 </e22> .
advise	drug1 dose should be reduced to half its normal dose when <e10> drug1 </e10> is administered concomitantly with <e20> drug2 </e20> .
advise	dosage adjustment of <e10> drug1 </e10> is advised when co - administered with <e21> drug2 </e21> .
advise	concomitant administration of <e10> drug1 </e10> and <e20> drug2 </e20> is not recommended .
advise	<e10> drug1 </e10> should not be used concomitantly with <e21> drug2 </e21> , quinidine , or isocarboxazid </e21> .
advise	thus , <e10> drug1 </e10> should be administered with caution to patients receiving <e21> drug2 </e21> or other drugs that inhibit the cyp3a4 isoenzyme , including antidepressants ( cholinesterase inhibitors [ terfenadine ] and imipramine ) , phenothiazines ( alprazolam ) and type _ 1c _ antiarrhythmics ( propafenone , flecainide ) .
advise	therefore , co - administration of <e11> drug1 </e11> with other strong cyp3a4 inhibitors ( e , g , , <e20> drug2 </e20> , ketoconazole , nefazodone , norfloxacin , ritonavir , etc ) should be approached with caution .
advise	concomitant use of <e10> drug1 </e10> and <e20> drug2 </e20> is not recommended .
advise	other 5 - ht1b / 1d _ agonists concomitant use of <e10> drug1 </e10> and <e20> drug2 </e20> is contraindicated .
advise	however , appropriate monitoring of these agents is recommended during concomitant treatment with <e11> drug1 </e11> and <e22> drug2 </e22> .
advise	caution should be exercised when administering <e11> drug1 </e11> to patients receiving <e22> drug2 </e22> .
advise	concomitant use of <e10> drug1 </e10> with other <e22> drug2 </e22> ( eg , phenergan , ergot _ alkaloids , dihydroergotamine ) is not recommended .
advise	drug - drug interactions given the potential for additive or potentiating effects with cns _ depressants , caution should be used when <e10> drug1 </e10> is administered with <e21> drug2 </e21> and other drugs that are used to treat bipolar disorder or schizophrenia .
advise	therefore , co - administration of <e10> drug1 </e10> with other drugs that are metabolized by this isoenzyme ( e , g , , amphotericin _ b , fluconazole , drug2 , <e20> drug2 </e20> , nefazodone , risperidone , and tricyclic _ antidepressants ( tcas ) and / or certain dopamine _ 1 _ receptor _ agonists ( draz ) should be approached with caution .
advise	consequently , concomitant administration of <e10> drug1 </e10> and <e20> drug2 </e20> is contraindicated .
advise	caution should be used when <e11> drug1 </e11> is administered concurrently with <e22> drug2 </e22> .
advise	concomitant use of <e10> drug1 </e10> and <e22> drug2 </e22> is not recommended .
advise	administration of <e11> drug1 </e11> with other drugs that inhibit synthesis of proteins , including <e20> drug2 </e20> , quinolone _ antibiotics , phenytoin , terfenadine , cimetidine , and amikacin , should be approached with caution .
advise	a dose increase of <e10> drug1 </e10> to 150 mg twice daily is recommended in patients taking <e20> drug2 </e20> .
advise	inhibitors of this enzyme , such as <e10> drug1 </e10> , should be administered with caution in patients receiving <e20> drug2 </e20> .
advise	this interaction should be given consideration in patients taking <e10> drug1 </e10> concurrently with <e20> drug2 </e20> .
advise	exert particular caution when administering <e11> drug1 </e11> with benzodiazepines ( e , g , , <e20> drug2 </e20> , triazolam , or midazolam ) , because of the potential for the drug to increase convulsion symptoms and to prolong the qt interval .
advise	<e10> drug1 </e10> should not be administered concomitantly with <e20> drug2 </e20> or drug2 - containing ( e , g , , cimetidine , diltiazem ) antacids .
advise	therefore , co - administration of <e10> drug1 </e10> with other hiv - 1 protease inhibitors ( e , g , , protease _ inhibitors , abacavir , <e21> drug2 </e21> and indinavir ) is not recommended .
advise	concomitant administration of <e10> drug1 </e10> and <e20> drug2 </e20> is not recommended .
advise	dose adjustment of <e10> drug1 </e10> may be required in patients receiving <e20> drug2 </e20> .
advise	therefore , co - administration of <e10> drug1 </e10> and other drugs that are metabolized by this isozyme , including <e20> drug2 </e20> , cisapride , indomethacin , and itraconazole , should be approached with caution .
advise	therefore , co - administration of <e11> drug1 </e11> with other drugs that are extensively metabolized by this isoenzyme such as certain antidepressants ( tricyclic _ antidepressants [ tcas ] and nortriptyline ) , phenothiazines ( thioridazine ) , <e22> drug2 </e22> , and drug2 _ subarmin , or agents that are substrates of this enzyme such as certain antidepressants ( tcas ) and drug2 ( tricyclic _ antidepressants [ tcas ] and haloperidol ) , or agents that are inhibitors of this enzyme ( such as certain antidepressants ( tcas ) and drug2 _ subarmin ) , should be approached with caution .
advise	therefore concomitant administration of <e10> drug1 </e10> and another <e20> drug2 </e20> ( e , g , , haloperidol ) should be approached with caution .
advise	therefore , co - administration of <e10> drug1 </e10> with other drugs that have a prolonged plasma concentration , such as ketoconazole , <e21> drug2 </e21> , itraconazole , and clarithromycin , should be approached with caution .
advise	if concomitant treatment with <e10> drug1 </e10> and <e20> drug2 </e20> is clinically warranted , the drug1 dose should be reduced by approximately 50 % while on the single - agent drug2 .
advise	caution should be exercised when administering <e10> drug1 </e10> to patients on <e20> drug2 </e20> therapy .
advise	<e10> drug1 </e10> dose should not exceed # mg every # hours in patients receiving cyp3a4 inhibitors ( e , g , , <e22> drug2 </e22> , itraconazole , ritonavir ) .
advise	concomitant administration with drugs that affect cyp3a4 activity : caution should be used when administering <e10> drug1 </e10> with drugs that increase cyp3a4 activity , including antidepressants , carbamazepine , indinavir , <e21> drug2 </e21> , quinidine , and voriconazole .
advise	caution should be exercised when administering <e10> drug1 </e10> to patients receiving <e22> drug2 </e22> .
advise	it may be necessary to adjust the dosage of <e11> drug1 </e11> when co - administered with <e22> drug2 </e22> , since these agents may decrease the elimination rate of the drug and thus increase the plasma concentration of its active metabolite , noradrenaline .
advise	if concomitant treatment with <e10> drug1 </e10> and <e20> drug2 </e20> is required , the maximum dose of drug2 should be reduced .
advise	therefore , co - administration of <e10> drug1 </e10> and other psychotropic _ drugs ( <e22> drug2 </e22> ) should be approached with caution .
advise	therefore , the concomitant use of <e10> drug1 </e10> and <e20> drug2 </e20> is contraindicated .
advise	therefore concomitant administration of <e10> drug1 </e10> and <e20> drug1 </e20> is contraindicated .
advise	thus , <e10> drug1 </e10> should not be taken in combination with <e21> drug2 </e21> , such as propafenone , flecainide , or encainide .
advise	aripiprazole dose should be adjusted in patients taking <e10> drug1 </e10> with mao _ inhibitors such as nortriptyline , imipramine , <e20> drug2 </e20> , and tricyclic _ antidepressants .
advise	therefore , co - administration of <e10> drug1 </e10> and <e20> drug2 </e20> is contraindicated .
advise	a dose adjustment of <e10> drug1 </e10> may be required when coadministered with <e21> drug2 </e21> .
advise	coadministration of <e10> drug1 </e10> and other <e22> drug2 </e22> should be undertaken with caution .
advise	therefore , co - administration of <e10> drug1 </e10> and <e20> drug2 </e20> is not recommended .
advise	nephrotoxic agents : caution should be used when <e11> drug1 </e11> is administered with agents known to increase plasma concentrations of drug1 ( e , g , , <e20> drug2 </e20> , saquinavir , erythromycin , clarithromycin , nefazadone , drug2 , nelfinavir , ritonavir , telithromycin , telithromycin ) and when these agents are co - administered .
advise	therefore , co - administration of <e10> drug1 </e10> with drugs that are extensively metabolized by this isozyme ( e , g , , phenothiazines , <e20> drug2 </e20> , and certain antidepressants ) should be approached with caution .
advise	therefore , co - administration of <e11> drug1 </e11> with other drugs that are extensively metabolized by this isozyme , including <e20> drug2 </e20> ( e , g , , cyclosporine a , tacrolimus , and others ) , isoflurane , and quinidine , should be approached with caution .
advise	drugs that should not be coadministered with <e11> drug1 </e11> antiarrhythmics : amiodarone , quinidine antihistamines : amantadine antimigraine : ergot _ derivatives antimycobacterial _ agents : rifampin benzodiazepines ( eg , <e20> drug2 </e20> and diltiazem )
advise	when used concomitantly , <e10> drug1 </e10> and <e22> drug2 </e22> should be administered at least # hours apart , and drug2 should be discontinued when the drug1 levels have stabilized .
advise	a dose increase in the subcutaneous dose of <e10> drug1 </e10> to a maximum of 50 mg daily should be considered when coadministered with <e20> drug2 </e20> .
advise	caution should be exercised when administering <e10> drug1 </e10> to patients receiving <e22> drug2 </e22> .
advise	therefore , cyp3a4 substrates that are extensively metabolized by this isozyme ( e , g , , ketoconazole , itraconazole , clarithromycin , <e10> drug1 </e10> , nefazadone , ritonavir ) should be administered with caution to patients receiving <e20> drug2 </e20> .
advise	caution should be used when administering <e10> drug1 </e10> with other <e22> drug2 </e22> .
advise	the concomitant use of <e10> drug1 </e10> with <e20> drug2 </e20> is contraindicated .
advise	<e11> drug1 </e11> should not be used with potent cyp3a4 inhibitors such as <e20> drug2 </e20> , itraconazole , nefazodone , ritonavir , erythromycin , or voriconazole .
advise	close supervision and dose adjustment of <e10> drug1 </e10> are recommended when coadministered with <e22> drug2 </e22> .
advise	therefore , cyp3a4 substrates ( e , g , , ketoconazole , <e10> drug1 </e10> , erythromycin , ritonavir ) should be administered with caution to patients on <e20> drug2 </e20> .
advise	caution should be used when administering <e11> drug1 </e11> to patients receiving <e22> drug2 </e22> therapy .
advise	<e10> drug1 </e10> should not be used with other drugs that are metabolized by cyp3a4 , including drugs that are substrates of this enzyme , such as phenobarbital , <e21> drug2 </e21> , indinavir , ritonavir , saquinavir , saquinavir , voriconazole , clarithromycin , and nelfinavir .
advise	consequently , concomitant administration of <e10> drug1 </e10> and <e20> drug2 </e20> is contraindicated .
advise	nafazodone , drug1 , cimetidine , and <e10> drug1 </e10> , should not be used in combination with <e20> drug2 </e20> .
advise	therefore , cyp3a4 substrates including , but not limited to , ketoconazole , <e10> drug1 </e10> , nelfinavir , ritonavir , saquinavir , indinavir , telithromycin , and ergot _ alkaloids ( ergotamine , dihydroergotamine ) should be cautiously co - administered with <e21> drug2 </e21> .
advise	therefore , co - administration of <e10> drug1 </e10> with <e22> drug2 </e22> is contraindicated .
advise	if concomitant treatment with <e11> drug1 </e11> and <e20> drug2 </e20> is indicated , an adjustment of the dosage of the individual component ( s ) of the treatment is advised .
advise	coadministration of <e10> drug1 </e10> with agents that are substrates for cyp3a4 isoenzymes , such as <e20> drug2 </e20> and itraconazole , should be approached with caution .
advise	caution should be exercised when administering <e10> drug1 </e10> to patients receiving <e20> drug2 </e20> , since the concomitant use of these two agents has not been studied in terms of their effects on gastrointestinal function .
advise	this interaction should be taken into consideration when administering <e10> drug1 </e10> to patients on <e20> drug2 </e20> therapy .
advise	carbamazepine : isoniazid : <e10> drug1 </e10> dosage should not exceed a maximum of # mg daily when co - administered with <e20> drug2 </e20> .
advise	therefore , co - administration of <e10> drug1 </e10> with drugs that are extensively metabolized by this isozyme , such as antidepressants , phenothiazines , type _ 1c _ antiarrhythmics ( e , g , , propafenone , flecainide ) , or <e20> drug2 </e20> ( e , g , , nefazodone ) , should be approached with caution .
advise	caution should be exercised when administering <e10> drug1 </e10> to patients receiving <e20> drug2 </e20> .
advise	therefore , <e10> drug1 </e10> and its related compounds should not be used in combination with <e20> drug2 </e20> .
advise	<e10> drug1 </e10> should not be used in combination with <e20> drug2 </e20> or other vasoconstrictive _ drugs .
advise	concomitant administration of <e10> drug1 </e10> and <e22> drug2 </e22> is contraindicated .
advise	theophylline serum levels should be monitored when <e10> drug1 </e10> is used concomitantly with <e20> drug2 </e20> .
advise	therefore , co - administration of <e10> drug1 </e10> and <e20> drug2 </e20> is contraindicated .
advise	however , prudent medical therapy should be maintained when <e10> drug1 </e10> is initiated or discontinued in patients receiving <e21> drug2 </e21> .
advise	accordingly , <e10> drug1 </e10> should not be administered to patients receiving <e22> drug2 </e22> or aripiprazole .
advise	<e10> drug1 </e10> should not be administered with <e21> drug2 </e21> or protease _ inhibitors ( e , g , , ketoconazole , clarithromycin , itraconazole ) .
advise	caution is therefore advised when <e11> drug1 </e11> is used with <e20> drug2 </e20> and beta - blockers .
advise	coadministration of <e10> drug1 </e10> with <e22> drug2 </e22> is not recommended .
advise	inhibitors of this isozyme , including <e11> drug1 </e11> and quinidine , should be used cautiously in patients treated with <e22> drug2 </e22> .
advise	caution should be exercised when <e10> drug1 </e10> is co - administered with certain <e22> drug2 </e22> such as imipramine , desipramine , paroxetine , sertraline , fluoxetine , escitalopram , fluvoxamine , sertraline , and desipramine , because these drugs increase blood levels of dopamine ( da ) and serotonin ( 5 - ht ) and cause symptoms of anhedonia ( depressions and a lack of pleasure ) .
advise	videx ( <e10> drug1 </e10> ) dose should be adjusted in patients who are being treated with <e22> drug2 </e22> .
advise	therefore , co - administration of <e11> drug1 </e11> with cyp3a4 substrates that are predominantly metabolized by this isozyme , such as <e20> drug2 </e20> , phenobarbital , cisapride , and isosorbide _ dinorbid , should be approached with caution .
advise	videx ( <e10> drug1 </e10> ) should be administered at least # hours before , # hours after , or # hours before , <e20> drug2 </e20> .
advise	it is suggested that when <e10> drug1 </e10> is administered concurrently with <e20> drug2 </e20> , the drug2 dose should be reduced by approximately 50 % to approximately 1 mg per day .
advise	this interaction should be taken into account when <e10> drug1 </e10> is co - administered with <e22> drug2 </e22> .
advise	based on adult studies , the prothrombin time and the drug2 time should not be used interchangeably in patients receiving <e12> drug1 </e12> with <e20> drug2 </e20> .
advise	therefore , co - administration of <e10> drug1 </e10> with other <e22> drug2 </e22> ( e , g , , haloperidol , risperidone , perphenazine , quinidine , thioridazine , thioridazine , triazolam , etc , ) is not recommended .
advise	close supervision and careful adjustment of the dose of <e10> drug1 </e10> are advised when used with <e20> drug2 </e20> .
advise	caution should be exercised when administering <e10> drug1 </e10> to patients receiving <e20> drug2 </e20> concurrently .
advise	if concomitant treatment with <e11> drug1 </e11> and <e22> drug2 </e22> is indicated , the dose of the initiating anticoagulant should be reduced and the anticoagulant dose increased .
advise	therefore , the concomitant administration of <e11> drug1 </e11> with <e22> drug2 </e22> should be avoided .
advise	interactions with mixed _ agonist / antagonist _ opioid _ analgesics : opioid _ analgesics ( including morphine , codeine , and <e10> drug1 </e10> ) should not be used with <e21> drug2 </e21> as they may increase the plasma concentrations of morphine and codeine .
advise	because of the possible interactions , co - administration of <e11> drug1 </e11> with other drugs that are extensively metabolized by this isozyme ( e , g , , ketoconazole , itraconazole , clarithromycin , nefazodone , <e20> drug2 </e20> , nefazadone , nelfinavir , nelfinavir / ritonavir , telithromycin , troleandomycin , zafirlukast ) should be approached with caution .
advise	consequently , concomitant administration of <e10> drug1 </e10> with <e20> drug2 </e20> is contraindicated .
advise	therefore , co - administration of <e10> drug1 </e10> and other drugs that are metabolized by this isozyme isoenzymes ( e , g , , methysergide , <e20> drug2 </e20> , propranolol , and flecainide ) should be approached with caution .
advise	caution should be used when administering <e11> drug1 </e11> with potent cyp3a4 inhibitors such as ketoconazole , clarithromycin , ritonavir , nelfinavir , and <e20> drug2 </e20> .
advise	<e10> drug1 </e10> should not be taken with other drugs known to prolong the qt interval , including certain antidepressants ( <e22> drug2 </e22> ) , phenothiazines ( tricyclic _ antidepressants [ tcas ] ) , and type _ 1c _ antiarrhythmics ( e , g , , propafenone and flecainide ) .
advise	brovana , as with other <e12> drug1 </e12> , should be given with caution to patients on <e20> drug2 </e20> .
advise	appropriate laboratory testing and monitoring of co - administration of <e11> drug1 </e11> with other <e22> drug2 </e22> is recommended .
advise	although the interactions observed in this study have not been evaluated in humans , co - administration of <e10> drug1 </e10> with other drugs that have a narrow therapeutic index such as amiodarone , itraconazole , or <e20> drug2 </e20> should be approached with caution .
advise	- drug1 : <e10> drug1 </e10> should be taken with caution in patients receiving <e20> drug2 </e20> , because lithium itself may potentiate its effects .
advise	therefore , co - administration of <e10> drug1 </e10> with other <e22> drug2 </e22> is not recommended .
advise	this interaction should be given consideration in patients taking <e12> drug1 </e12> concomitantly with <e22> drug2 </e22> .
advise	this interaction should be given consideration in patients taking <e11> drug1 </e11> concomitantly with <e22> drug2 </e22> .
advise	since pletal is a potent inhibitor of angiotensin converting enzyme ( ace ) , co - administration of <e11> drug1 </e11> with ace - inhibitors ( e , g , , sirolimus , <e20> drug2 </e20> ) should be approached with caution .
advise	when <e11> drug1 </e11> is administered concomitantly with <e22> drug2 </e22> , titration of the dose of drug2 should be undertaken cautiously .
advise	therefore , it is recommended that <e10> drug1 </e10> not be administered to patients receiving <e22> drug2 </e22> , or to patients receiving intravenous cortico drug2 .
advise	special consideration should be given to <e11> drug1 </e11> in patients on <e20> drug2 </e20> therapy and in those receiving anticoagulant or heparin therapy .
advise	therefore , co - administration of <e11> drug1 </e11> with other drugs that are extensively metabolized by this isozyme ( e , g , , ketoconazole , itraconazole , nefazadone , clarithromycin , drug2 , nelfinavir , <e20> drug2 </e20> , saquinavir , indinavir , telithromycin ) should be approached with caution .
advise	interactions with mixed _ agonist / antagonist _ opioid _ analgesics : the combination of <e10> drug1 </e10> and <e20> drug2 </e20> is contraindicated .
advise	therefore , cyp3a4 substrates with a narrow therapeutic index such as <e10> drug1 </e10> and midazolam should not be administered concurrently with <e20> drug2 </e20> .
advise	when used concomitantly , <e10> drug1 </e10> and <e20> drug2 </e20> should be administered at least # hours apart .
advise	dosage adjustment of <e10> drug1 </e10> may be necessary when co - administered with <e22> drug2 </e22> .
advise	caution should be exercised when <e10> drug1 </e10> is administered concurrently with <e22> drug2 </e22> .
advise	consequently , it is recommended that <e11> drug1 </e11> not be used in combination with <e20> drug2 </e20> or drug2 _ salicylate .
advise	drugs that may depress cyp3a4 activity ( e , g , , ketoconazole , itraconazole , clarithromycin , <e10> drug1 </e10> , ritonavir , nefazadone ) should not be administered to patients receiving <e20> drug2 </e20> - containing medications .
advise	therefore , co - administration of <e10> drug1 </e10> and <e22> drug2 </e22> is not recommended .
advise	administration of <e11> drug1 </e11> with other <e22> drug2 </e22> ( eg , phenytoin , cyclosporine , diltiazem , clarithromycin ) should be approached with caution .
advise	<e10> drug1 </e10> should not be used in combination with other <e22> drug2 </e22> _ drugs .
advise	if concomitant treatment with <e11> drug1 </e11> and <e20> drug2 </e20> is clinically warranted , reduction of drug2 dosage may be necessary .
advise	<e11> drug1 </e11> should be given with caution to patients on chronic <e20> drug2 </e20> therapy or taking larger or long - acting potentiates .
advise	therefore , extreme caution should be exercised when administering or taking <e11> drug1 </e11> with other <e22> drug2 </e22> .
advise	therefore , co - administration of <e10> drug1 </e10> with <e22> drug2 </e22> is contraindicated .
advise	caution is advised when administering <e10> drug1 </e10> with other <e22> drug2 </e22> .
advise	methotrexate : caution should be used if <e10> drug1 </e10> is administered concurrently with <e21> drug2 </e21> .
advise	the concomitant use of <e10> drug1 </e10> and other cyp3a4 inhibitors ( e , g , , <e20> drug2 </e20> , nelfinavir , clarithromycin , ritonavir ) is contraindicated .
advise	therefore , close monitoring of patients is advised in those taking <e11> drug1 </e11> concomitantly with <e20> drug2 </e20> or quinine .
advise	5ht3 _ antagonists : based on in vitro studies , the use of <e10> drug1 </e10> with <e20> drug2 </e20> is not recommended .
advise	<e11> drug1 </e11> should not be used with phenothiazines , cyclosporine , <e20> drug2 </e20> , or ritonavir .
advise	dose adjustment of <e11> drug1 </e11> in patients receiving <e22> drug2 </e22> is not recommended .
advise	consequently , concomitant administration of <e11> drug1 </e11> and <e22> drug2 </e22> is contraindicated .
advise	caution should be used if <e10> drug1 </e10> is given to a patient receiving a <e21> drug2 </e21> concurrently .
advise	consequently , concomitant administration of <e10> drug1 </e10> and <e20> drug2 </e20> is contraindicated .
advise	caution should be exercised if <e10> drug1 </e10> is administered with <e22> drug2 </e22> or protease _ inhibitors .
advise	<e11> drug1 </e11> should not be used concomitantly with <e22> drug2 </e22> agents , which include phenothiazines , carbamazepine , and triazolam .
advise	caution should be used if <e11> drug1 </e11> is administered concurrently with <e22> drug2 </e22> .
advise	caution should be used if <e11> drug1 </e11> is administered to patients receiving <e22> drug2 </e22> .
advise	a dose adjustment of <e10> drug1 </e10> may be required when used in combination with <e20> drug1 </e20> .
advise	at least # weeks should elapse between <e10> drug1 </e10> and <e22> drug2 </e22> administration .
advise	<e10> drug1 </e10> should not be given with other strong cyp3a4 inhibitors ( e , g , , ketoconazole , erythromycin , clarithromycin , <e20> drug2 </e20> , nefazodone , ritonavir ) or when there is a risk of drug interaction with an oral cyp3a4 inhibitor ( e , g , , ergot _ alkaloids ) .
advise	it is suggested that <e11> drug1 </e11> be given at least # hours prior to or # hours after <e20> drug2 </e20> .
advise	nafazodone , fluvoxamine , cimetidine , and <e10> drug1 </e10> should not be used concomitantly with <e20> drug2 </e20> because of potential drug interactions .
advise	nevertheless , caution is advised when <e11> drug1 </e11> is administered to patients receiving <e20> drug2 </e20> .
advise	therefore , co - administration of <e11> drug1 </e11> with other drugs that are extensively metabolized by this isozyme ( e , g , , <e20> drug2 </e20> , itraconazole , clarithromycin , rifampin , and nefazadone ) should be approached with caution .
advise	during concomitant therapy with <e10> drug1 </e10> and <e22> drug2 </e22> , dose adjustments of the drug2 dosage may be necessary .
advise	co - administration of <e11> drug1 </e11> with drugs that are extensively metabolized by this isozyme , such as certain antidepressants ( e , g , , fluoxetine and paroxetine ) , phenothiazines ( e , g , , type _ 1c _ antiarrhythmics [ e , g , , propafenone , flecainide , and encainide ] , and <e20> drug2 </e20> ) , or agents that are extensively metabolized by this enzyme , such as certain antidepressants ( e , g , , nortriptyline and imipramine ) , should be approached with caution .
advise	therefore , co - administration of <e11> drug1 </e11> and <e20> drug2 </e20> is contraindicated .
advise	therefore , co - administration of <e11> drug1 </e11> with other <e22> drug2 </e22> ( e , g , , fluvoxamine , paroxetine , citalopram , fluvoxamine , fluvoxamine _ hcl , fluvoxamine _ hcl _ hcl ) should be approached with caution .
advise	this interaction should be given consideration when administering <e10> drug1 </e10> to patients on <e22> drug2 </e22> therapy .
advise	therefore , co - administration of <e10> drug1 </e10> with other drugs that are extensively metabolized by this isozyme , including certain antidepressants ( tricyclic _ antidepressants [ tcas ] , including nortriptyline [ <e21> drug2 </e21> ] , and imipramine [ imipramine ] ) , phenothiazines [ triazolam ] , and type _ 1c _ antiarrhythmics ( e , g , , propafenone ) , should be approached with caution .
advise	coadministration of <e10> drug1 </e10> with <e22> drug2 </e22> is not recommended .
advise	caution is advised when <e11> drug1 </e11> is used with agents that are metabolized by this isoenzyme , including ketoconazole , clarithromycin , indinavir , nefazodone , <e20> drug2 </e20> , and itraconazole .
advise	the concomitant use of <e10> drug1 </e10> and <e22> drug2 </e22> is not recommended .
advise	however , appropriate monitoring of dose is recommended when <e10> drug1 </e10> is administered with <e20> drug2 </e20> .
advise	however , when any of these products are used concomitantly , patients should be warned that the concomitant use of <e10> drug1 </e10> and <e20> drug1 </e20> is contraindicated .
advise	coadministration of <e10> drug1 </e10> with agents that are metabolized by cyp3a4 isoenzyme including atazanavir , clarithromycin , indinavir , nefazadone , nelfinavir , drug2 , saquinavir , telithromycin and <e20> drug2 </e20> is not recommended .
advise	<e10> drug1 </e10> should not be given to patients taking <e22> drug2 </e22> ( chlordiazepoxide , haloperidol , risperidone , thioridazine , and quinidine ) .
advise	therefore , concurrent use of <e11> drug1 </e11> and other <e22> drug2 </e22> is contraindicated .
advise	it is recommended that patients taking <e11> drug1 </e11> not exceed a maximum dose of 300 mg of <e22> drug2 </e22> within # hours of each other .
advise	caution should be exercised if <e10> drug1 </e10> is co - administered with <e20> drug2 </e20> .
advise	when <e11> drug1 </e11> is administered concurrently with other <e22> drug2 </e22> , the recommended dose should be reduced by approximately 30 % ( from # mg to # mg ) .
advise	it may be necessary to increase the dosage of <e11> drug1 </e11> before initiating or changing therapy with <e20> drug2 </e20> .
advise	therefore , # to # mg <e12> drug1 </e12> should not be administered concomitantly with <e20> drug2 </e20> .
advise	therefore , co - administration of <e10> drug1 </e10> with <e20> drug2 </e20> is contraindicated .
advise	<e11> drug1 </e11> should not be taken in combination with other <e22> drug2 </e22> , beta - blockers or potent opioids .
advise	a dose adjustment of <e10> drug1 </e10> is therefore required in patients receiving <e20> drug2 </e20> .
advise	because of drug1 - related hypersensitivity reactions , use of <e10> drug1 </e10> within # hours before or # hours after <e21> drug2 </e21> is not recommended .
advise	for adult - onset diabetics , co - administration of <e10> drug1 </e10> and <e22> drug2 </e22> is contraindicated .
advise	dose reduction of <e11> drug1 </e11> may be required in patients receiving concomitant <e22> drug2 </e22> therapy .
advise	therefore , co - administration of <e11> drug1 </e11> with other drugs that are extensively metabolized by this isozyme , including inhibitors of cyp3a4 ( e , g , , ketoconazole , clarithromycin , nelfinavir ) , or of p - glycoprotein ( e , g , , <e20> drug2 </e20> ) , should be approached with caution .
advise	caution should be exercised when administering <e10> drug1 </e10> to patients receiving <e20> drug2 </e20> .
advise	concomitant administration of <e11> drug1 </e11> with <e22> drug2 </e22> should be approached with caution .
advise	before taking <e10> drug1 </e10> , tell your doctor if you are taking any of the following medicines : aspirin or another salicylate such as magnesium / choline _ salicylate ( trilisate ) ; magnesium _ salicylate ( maganet ) ; diltiazem ( trilisate ) ; <e20> drug2 </e20> ( descriptivon ) ; or ritonavir ( tenofovir ) .
advise	caution should be used when administering or taking <e11> drug1 </e11> with phenothiazines ( e , g , , <e20> drug2 </e20> , fluvoxamine , flecainide ) and other sympathomimetic _ drugs ( e , g , , quinidine , digoxin ) , since the action of these agents may be potentiated .
advise	<e10> drug1 </e10> should not be administered with other <e22> drug2 </e22> , including quinidine ( trilisate ) , which has been withdrawn from the us market for this indication .
advise	inhibitors of this isozyme , such as clarithromycin , <e10> drug1 </e10> , and azithromycin , should not be used concurrently with <e21> drug2 </e21> .
advise	therefore , use of <e10> drug1 </e10> with <e20> drug2 </e20> is contraindicated .
advise	<e10> drug1 </e10> should be used with caution in patients with severe and / or intolerant hypersensitivity reactions to other <e22> drug2 </e22> ( e , g , , warfarin , ritonavir , thrombin , and antithrombin ) , antithrombin ( e , g , , protease _ inhibitor ) , or antithrombin _ antagonists ( e , g , , amiodarone , flecainide ) .
advise	multivitamins , or other vitamins / minerals ( e , g , , <e10> drug1 </e10> , vitamin c , ferrous _ sulfate , or vitamin a ) should not be given simultaneously with <e21> drug2 </e21> .
advise	<e10> drug1 </e10> should not be administered to patients receiving inhibitors of cyp3a4 ( e , g , , <e22> drug2 </e22> , indinavir , clarithromycin , and nelfinavir ) .
advise	considerable caution should be exercised in administering <e11> drug1 </e11> to patients receiving <e20> drug2 </e20> or another nsaid .
advise	if concomitant treatment with <e10> drug1 </e10> and <e20> drug2 </e20> is initiated , a lower dose of drug1 may be needed .
advise	multivitamins , or other forms of vitamin c ( <e11> drug1 </e11> ) should not be taken concurrently with <e22> drug2 </e22> .
advise	before taking <e10> drug1 </e10> , tell your doctor if you are taking another drug that could increase your serum levels of phenobarbital ( eg , fluconazole , <e20> drug2 </e20> , itraconazole , drug1 ) , or if you are taking any other drugs that can lower the serum levels of phenobarbital ( eg , certain antidepressants , certain antipsychotics ) .
advise	dosage adjustment of <e11> drug1 </e11> may be necessary when co - administered with other <e22> drug2 </e22> ( e , g , , ketoconazole , itraconazole , itraconazole _ hcl , nefazadone , ritonavir ) .
advise	close observation of patients receiving <e12> drug1 </e12> may be required when <e22> drug2 </e22> are initiated or withdrawn .
advise	caution should be used when administering <e11> drug1 </e11> with cyp3a4 substrates that have a narrow therapeutic index ( e , g , , <e20> drug2 </e20> , clarithromycin , indinavir , nefazadone ) .
advise	therefore , if <e10> drug1 </e10> is to be used in combination with <e20> drug2 </e20> , its use should be preceded by careful observation of the patient ' s clinical condition , and adjustments in dosage and intervals of dosing should be made accordingly .
advise	particular caution is warranted when administering <e11> drug1 </e11> to patients receiving <e22> drug2 </e22> .
advise	of particular importance , co - administration of <e11> drug1 </e11> and <e20> drug2 </e20> is not recommended .
advise	nephrotoxic agents : caution should be used if <e11> drug1 </e11> is used with agents known to cause nephrotoxicity ( e , g , , <e20> drug2 </e20> , itraconazole , fluconazole , clarithromycin , gentamicin , and tobramycin ) .
advise	therefore , co - administration of <e10> drug1 </e10> and other psychotropic _ drugs ( including alcohol , nicotine , and <e21> drug2 </e21> ) should be approached with caution .
advise	a 5 - mg <e10> drug1 </e10> dose should not be exceeded during or after <e21> drug2 </e21> therapy .
advise	concomitant administration of <e10> drug1 </e10> and <e20> drug2 </e20> is contraindicated .
advise	before taking <e10> drug1 </e10> , tell your doctor if you are taking any of the following medicines : amiodarone or astemizole ( for more than 3 weeks ) ; <e20> drug2 </e20> ( for more than 3 weeks ) ; phenobarbital ( for more than 3 weeks ) ; nefazodone ( for more than 1 week ) ; salsalate ( for more than 1 week ) ; or ergotamine ( for more than 1 week ) .
advise	the intake of <e11> drug1 </e11> and <e20> drug2 </e20> within # days should be limited to # days .
advise	before taking <e10> drug1 </e10> , tell your doctor if you are taking any of the following medicines : - aspirin or another salicylate such as magnesium or vitamin d3 ( eg , <e21> drug2 </e21> ) ;
advise	concomitant administration of <e10> drug1 </e10> and other <e22> drug2 </e22> is contraindicated .
advise	therefore , co - administration of <e11> drug1 </e11> and <e20> drug2 </e20> is contraindicated .
advise	consequently , concomitant administration of <e10> drug1 </e10> and <e22> drug2 </e22> is contraindicated .
advise	in addition , drugs that inhibit cyp3a4 activity ( e , g , , ketoconazole , clarithromycin , <e10> drug1 </e10> , nefazodone , ritonavir , nelfinavir ) should be administered with caution to patients receiving <e20> drug2 </e20> .
advise	aspirin : aspirin concentrations should be monitored when <e10> drug1 </e10> is coadministered with <e21> drug2 </e21> .
advise	special consideration should be given to patients taking <e12> drug1 </e12> concomitantly with <e22> drug2 </e22> or other agents with a similar name ( e , g , , anesthetics , anesthetics - like agents , pentazocine , or pentazocine ) .
advise	plasma valproate concentration should be closely monitored if <e11> drug1 </e11> is administered concurrently with <e20> drug2 </e20> .
advise	therefore , extreme caution should be used when administering <e11> drug1 </e11> to patients on <e22> drug2 </e22> or other drugs that may inhibit calcium - binding proteins , such as ritonavir , clarithromycin , and protease _ inhibitors ( e , g , , amikacin , telithromycin ) .
advise	because both of these agents are potent inhibitors of cyp3a4 activity , caution is advised when <e10> drug1 </e10> is co - administered with agents that are substrates for cyp3a4 , including <e21> drug2 </e21> , anophylline , quinine , nefazadone , nelfinavir , ritonavir , saquinavir , telithromycin , and voriconazole .
advise	coadministration of <e11> drug1 </e11> with other agents known to prolong the qt interval , including <e22> drug2 </e22> , digoxin , steroids , or thioridazine , should be approached with caution .
advise	<e10> drug1 </e10> should be administered with caution to patients taking other psychotropic _ analgesics ( tricyclic _ antidepressants , <e22> drug2 </e22> , or other agents that act via the 5 - ht3 _ receptor ) or to patients receiving or already receiving a psychoactive _ drug such as alcohol .
advise	patients who have received <e10> drug1 </e10> therapy for any length of time should be closely monitored when <e20> drug2 </e20> is initiated in these patients .
advise	<e10> drug1 </e10> should not be administered to patients who have received other <e22> drug2 </e22> within # days .
advise	caution should be exercised if <e11> drug1 </e11> is given to patients receiving <e22> drug2 </e22> .
advise	concomitant administration of <e10> drug1 </e10> with <e20> drug2 </e20> is contraindicated .
advise	this interaction should be given consideration in patients taking <e10> drug1 </e10> concomitantly with <e21> drug2 </e21> .
advise	consequently , <e10> drug1 </e10> should not be administered to patients receiving a <e20> drug2 </e20> ( e , g , , phenobarbital ) # mg · kg⁻¹ · day⁻¹ .
advise	therefore , co - administration of <e10> drug1 </e10> with other drugs that are extensively metabolized by this isozyme , including antidepressants ( e , g , , nortriptyline , paroxetine , fluoxetine ) , antipsychotics ( e , g , , haloperidol , risperidone ) , and type _ 1c _ antiarrhythmics ( e , g , , propafenone ) , or agents with a narrow therapeutic index , such as intravenous <e20> drug2 </e20> , should be approached with caution .
advise	therefore , co - administration of <e10> drug1 </e10> and other <e20> drug2 </e20> is contraindicated .
advise	<e11> drug1 </e11> should not be used concomitantly with other <e22> drug2 </e22> ( including ketoconazole , itraconazole , voriconazole , clarithromycin , erythromycin , nefazadone , troleandomycin , gentamicin , moxifloxacin , and tobramycin ) or with drug2 known to prolong the prothrombin time ( e , g , , intravenous aminoglycosides , ritonavir , telithromycin ) .
advise	therefore , use of <e10> drug1 </e10> with other drugs that are extensively metabolized by this isozyme ( e , g , , ketoconazole , <e20> drug2 </e20> , clarithromycin , nefazadone , ritonavir , etc , ) should be approached with caution .
advise	drugs that should not be coadministered with <e10> drug1 </e10> drugs that should not be coadministered with an <e20> drug2 </e20> drugs that should not be coadministered with an alcoholic beverage drugs that should not be coadministered with an antacids drugs that should not be coadministered with an antihistamine drugs that should not be coadministered with an analgesic drugs that should not be coadministered with an antimycobacterial drugs
advise	therefore , co - administration of <e10> drug1 </e10> with <e22> drug2 </e22> is contraindicated .
advise	based on adult studies , <e10> drug1 </e10> should not be used in combination with <e22> drug2 </e22> .
advise	concomitant use of <e10> drug1 </e10> and <e20> drug2 </e20> is not recommended .
advise	the concomitant use of <e10> drug1 </e10> and <e22> drug2 </e22> is not recommended .
advise	inhibitors of this enzyme , including aspirin , amiodarone , <e10> drug1 </e10> , nefazodone , quinidine , ritonavir , and saquinavir , should be administered with caution to patients receiving <e21> drug2 </e21> .
advise	a dose increase of <e11> drug1 </e11> to 2 mg twice daily is recommended in patients on concomitant <e22> drug2 </e22> therapy .
advise	concomitant administration of <e10> drug1 </e10> with <e20> drug2 </e20> is contraindicated .
advise	a dose increase in the # mg daily of <e10> drug1 </e10> to # mg daily should be considered in patients taking <e21> drug2 </e21> or other antihistamines .
advise	since drug2 is extensively metabolized by cyp3a4 , it is recommended that co - administration of <e10> drug1 </e10> and <e21> drug2 </e21> be approached with caution .
advise	therefore , co - administration of <e10> drug1 </e10> and other <e20> drug2 </e20> is not recommended .
advise	caution should be exercised when administering <e10> drug1 </e10> to patients receiving <e21> drug2 </e21> .
advise	nevertheless , caution is advised in the co - administration of <e10> drug1 </e10> and <e20> drug1 </e20> .
advise	this interaction should be given consideration when <e10> drug1 </e10> and <e20> drug2 </e20> are co - administered .
advise	therefore , co - administration of <e10> drug1 </e10> with drugs that are metabolized by this isozyme and inhibit its activity ( e , g , , ketoconazole , itraconazole , clarithromycin , <e20> drug2 </e20> , nelfinavir ) should be approached with caution .
advise	a dose increase of <e10> drug1 </e10> to # mg / day is recommended in patients receiving <e22> drug2 </e22> .
advise	caution should be exercised when administering <e11> drug1 </e11> to patients receiving <e20> drug2 </e20> .
advise	nephrotoxic agents : caution should be used when administering <e11> drug1 </e11> with agents known to prolong qtc interval ( e , g , , <e20> drug2 </e20> , itraconazole ) and with agents known to prolong the qtc interval ( e , g , , heparin ) , since prolongation of the qtc interval can be a predictor of qtc prolongation .
advise	methotrexate : caution should be used when <e10> drug1 </e10> is administered concurrently with <e20> drug2 </e20> .
advise	concomitant use of <e10> drug1 </e10> with <e20> drug2 </e20> is contraindicated .
advise	patients already stabilized on <e10> drug1 </e10> should be observed carefully if they are to be switched to <e20> drug2 </e20> .
advise	in simultaneous treatment with <e10> drug1 </e10> and <e20> drug2 </e20> , a titration of drug2 from 10 - 30 microg / day to 0 - 30 microg / day may be necessary .
advise	although the interactions observed in this study have not been studied in more detail , caution is advised when administering <e10> drug1 </e10> with other <e22> drug2 </e22> ( tricyclic _ drug2 , for example ) or stimulants ( alcohol ) .
advise	drugs that should not be coadministered with <e11> drug1 </e11> - <e22> drug2 </e22>
advise	patients should be cautioned to take <e10> drug1 </e10> during the period of <e20> drug2 </e20> treatment .
advise	nafazodone , <e10> drug1 </e10> , or desipramine should not be used in combination with <e20> drug2 </e20> .
advise	in addition , drugs that are metabolized by cyp3a4 , including <e10> drug1 </e10> , should be coadministered with <e20> drug2 </e20> .
advise	<e11> drug1 </e11> should be taken with caution in patients receiving or taking <e20> drug2 </e20> , fluconazole , gentamicin , or tobramycin .
advise	caution is advised in the use of <e11> drug1 </e11> in patients taking <e20> drug2 </e20> concurrently .
advise	caution should be exercised when administering <e10> drug1 </e10> to patients on <e22> drug2 </e22> therapy .
advise	a dose increase of <e10> drug1 </e10> to 5 mg / day is recommended when co - administered with <e21> drug2 </e21> .
advise	drugs that induce cns depressant effects ( e , g , , <e10> drug1 </e10> , pentazocine , methadone , etc ) , or drugs that cause a prolongation of the qt interval ( e , g , , isoflurane , fentanyl , etc ) , should not be used concurrently with <e22> drug2 </e22> .
advise	this interaction should be given consideration in patients taking <e10> drug1 </e10> concomitantly with <e22> drug2 </e22> .
advise	caution should be exercised when <e10> drug1 </e10> is used in combination with <e22> drug2 </e22> as treatment of patients receiving this combination is not recommended .
advise	in addition , most oral <e10> drug1 </e10> tablets should be taken with food or at least 1 hour before or after food containing <e21> drug2 </e21> .
advise	oral <e12> drug1 </e12> should not be used with other <e21> drug1 </e21> or other hormones , including hormone - releasing agents ( e , g , , tamoxifen ) , because they may interfere with the proper action of these agents on the uterus and ovaries .
advise	therefore , co - administration of <e10> drug1 </e10> and <e20> drug2 </e20> is contraindicated .
advise	consequently , concomitant administration of <e10> drug1 </e10> and <e20> drug2 </e20> is contraindicated .
advise	before taking <e10> drug1 </e10> , tell your doctor if you are taking any of the following medicines : a drug2 _ analog ( a <e22> drug2 </e22> ) , a nonsteroidal _ anti - inflammatory _ agent ( a ketoprofen ) , or an antipsychotic ( a haloperidol ) .
advise	therefore , co - administration of <e10> drug1 </e10> with other drugs that are metabolized by this isozyme , including phenothiazines , carbamazepine , and <e20> drug2 </e20> ( e , g , , propafenone , flecainide and encainide ) , should be approached with caution .
advise	because drug1 is metabolized by cytochrome p - 450 , co - administration of <e10> drug1 </e10> and other cyp3a4 inhibitors ( e , g , , <e20> drug2 </e20> , ritonavir , clarithromycin ) should be approached with caution .
advise	therefore , co - administration of <e10> drug1 </e10> and <e22> drug2 </e22> is not recommended .
advise	if concomitant treatment with <e10> drug1 </e10> and <e20> drug2 </e20> is clinically warranted , appropriate observation of the patient is advised .
advise	caution should be exercised if <e10> drug1 </e10> is given concurrently with <e20> drug2 </e20> .
advise	based on clinical experience , the <e10> drug1 </e10> dose should not exceed a maximum of 300 mg twice daily when administered with a <e20> drug2 </e20> .
advise	it is advisable to monitor patients receiving <e10> drug1 </e10> , who are taking <e21> drug2 </e21> .
advise	therefore , co - administration of <e11> drug1 </e11> with other antidepressants , phenothiazines , or other classes of drugs that are metabolized by this isoenzyme ( e , g , , ketoconazole , fluvoxamine , <e20> drug2 </e20> , etc ) should be approached with caution .
advise	if concomitant treatment with <e10> drug1 </e10> and <e20> drug2 </e20> is indicated , appropriate observation of the patient is advised .
advise	therefore , co - administration of <e11> drug1 </e11> with other <e22> drug2 </e22> ( e , g , , nortriptyline , imipramine , desipramine , fluoxetine , paroxetine , sertraline , sertraline , fluvoxamine , sertraline , fluvoxamine ) should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .
advise	because drug1 may increase intracranial pressure , use of <e10> drug1 </e10> within # hours of <e20> drug2 </e20> use should be approached with caution .
advise	close observation of the patient is required while <e10> drug1 </e10> is administered concomitantly with <e20> drug2 </e20> .
advise	drugs that should not be coadministered with <e11> drug1 </e11> : amiodarone , <e20> drug2 </e20> , indomethacin , ketoconazole , nefazadone , phenytoin
advise	consequently , concomitant administration of <e10> drug1 </e10> and <e20> drug2 </e20> is contraindicated .
advise	<e10> drug1 </e10> should not be used in patients taking other <e22> drug2 </e22> or hmg - coa _ reductase _ inhibitors ( eg , erythromycin or minocycline ) .
advise	drugs that may decrease plasma drug2 levels ( e , g , , ketoconazole , <e10> drug1 </e10> , indinavir ) should be used cautiously with <e20> drug2 </e20> - lowering agents .
advise	interactions with mixed _ agonist / antagonist _ drug2 : clonidine , nortriptyline , nalbuphine , desipramine , <e10> drug1 </e10> , nalbuphine , disulfiram and ergot _ alkaloids ( ergotamine , dihydroergotamine ) should be administered with caution to patients taking <e20> drug2 </e20> .
advise	the concomitant use of <e10> drug1 </e10> with <e22> drug2 </e22> is contraindicated .
advise	therefore , co - administration of <e10> drug1 </e10> and drugs that are metabolized by this isozyme , including antidepressants ( tricyclic _ antidepressants , other antidepressants , other <e22> drug2 </e22> ) , phenothiazines ( type _ 1c _ antiarrhythmics ) , or type _ 2c _ antiarrhythmics ( other benzodiazepines ) , should be approached with caution .
advise	consequently , concomitant administration of <e10> drug1 </e10> with <e20> drug2 </e20> is contraindicated .
advise	therefore , # to # mg <e10> drug1 </e10> daily dose should be reduced by 50 % in patients taking <e21> drug2 </e21> .
advise	when <e11> drug1 </e11> is co - administered with other <e22> drug2 </e22> ( e , g , , sotalol , paroxetine , fluoxetine , sertraline , sertraline , fluvoxamine ) , the recommended dose of the canabinene / paroxetine combination should be reduced to one - third of the original dose .
advise	therefore , co - administration of <e10> drug1 </e10> with other strong cyp3a4 inhibitors ( e , g , , ketoconazole , clarithromycin , nefazodone , <e20> drug2 </e20> , ritonavir , nelfinavir ) should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .
advise	drug1 : <e12> drug1 </e12> should not be administered to patients with a history of or current treatment with <e22> drug2 </e22> or other anesthetics .
advise	caution should be exercised when administering <e10> drug1 </e10> to patients receiving <e20> drug2 </e20> or drug2 - type agents because of possible additive effects .
advise	<e10> drug1 </e10> should not be used with other <e22> drug2 </e22> ( particularly barbiturates ) , benzodiazepines , phenothiazines , or tricyclic _ antidepressants ( e , g , , imipramine , paroxetine , fluoxetine , sertraline ) .
advise	thus , when <e11> drug1 </e11> is co - administered with other <e22> drug2 </e22> , such as phenylbutazone , it is recommended that the phenylbutazone dose should be reduced by at least 50 % .
advise	exert particular caution when administering <e10> drug1 </e10> with other drugs known to prolong hypotension and , when coadministered , especially <e22> drug2 </e22> or phenothiazines .
advise	plasma drug1 concentration should be monitored to ensure that <e10> drug1 </e10> is not being used in combination with <e20> drug2 </e20> .
advise	in simultaneous treatment of <e11> drug1 </e11> and other drugs that affect thyroid function ( e , g , , anticholinergic _ drugs , <e20> drug2 </e20> , thyroid _ stimulating _ agents , and antiglobulin _ agents ) , adjustments of the dosage of drug1 may be required .
advise	<e11> drug1 </e11> should be administered with caution to patients receiving other <e20> drug2 </e20> ( such as , but not limited to , astemizole , itraconazole , troleandomycin , or clarithromycin ) and not allowed to enter a drug infusion ( or even infusion reservoir ) until the end of the infusion .
advise	should it be desired to use <e11> drug1 </e11> in combination with <e20> drug2 </e20> , the maximum dose of drug1 should be reduced to a minimum of one - tenth of the usual dose .
advise	administration of <e11> drug1 </e11> within # hours of initiating therapy with <e22> drug2 </e22> should be approached with caution .
advise	because of its potential effect on the metabolism of agents that are metabolized by cyp3a4 , caution should be exercised when <e11> drug1 </e11> is coadministered with other drugs that are extensively metabolized by this isozyme ( e , g , , phenobarbital , <e20> drug2 </e20> , quinidine , fluvoxamine , and theophylline ) .
advise	based on adult data and preclinical studies , <e10> drug1 </e10> should be administered at least # hours before <e21> drug2 </e21> is to be administered .
advise	coadministration of <e10> drug1 </e10> with <e20> drug2 </e20> is contraindicated .
advise	as with most other drugs of abuse , caution should be used when <e10> drug1 </e10> is co - administered with opioids , sedatives , anesthetics , and anesthetics ( including anesthetics ) , phenothiazines , <e20> drug2 </e20> , or carbamazepine .
advise	avoid the use of <e11> drug1 </e11> in patients receiving systemic corticosteroids or <e22> drug2 </e22> and aminosalicylic _ acid .
advise	a dose increase of <e11> drug1 </e11> to # mg / day is recommended when used with oral <e22> drug2 </e22> .
advise	drug1 : <e10> drug1 </e10> should not be given concurrently with <e22> drug2 </e22> or nelfinavir .
advise	therefore , cyp3a4 substrates and inhibitors of cytochrome p450s , such as <e10> drug1 </e10> , clarithromycin , and ritonavir , should be administered with caution to patients receiving <e21> drug2 </e21> .
advise	dosage adjustment of <e11> drug1 </e11> may be necessary when co - administered with <e20> drug2 </e20> .
advise	however , prudent medical practice requires that <e10> drug1 </e10> and <e20> drug2 </e20> not be co - administered with each other .
advise	close supervision and consideration of the effects of <e10> drug1 </e10> and other benzodiazepines when co - administered with <e21> drug2 </e21> are warranted .
advise	caution should be exercised when <e11> drug1 </e11> is given concurrently with <e20> drug2 </e20> .
advise	dosage adjustment of <e11> drug1 </e11> is not recommended in patients receiving <e20> drug2 </e20> .
advise	<e11> drug1 </e11> should not be used concomitantly with <e20> drug2 </e20> or other protease _ inhibitors ( e , g , , ketoconazole , itraconazole , ritonavir , clarithromycin ) .
advise	when initiating a treatment with <e10> drug1 </e10> and <e20> drug2 </e20> concurrently , an interval of at least # days between the two drugs is recommended .
advise	inhibitors of this enzyme ( e , g , , amikacin , <e10> drug1 </e10> , tobramycin , tobramycin / mannitol , drug2 , amikacin , tobramycin , ciprofloxacin , tobramycin / mannitol , clarithromycin , nafazodone , nelfinavir ) should be administered with caution to patients receiving <e20> drug2 </e20> .
advise	caution should be used if <e10> drug1 </e10> is administered with <e22> drug2 </e22> substrates .
advise	drug1 : <e12> drug1 </e12> should not be administered to patients receiving warfarin ( e , g , , <e20> drug2 </e20> or zalcitabine ) .
advise	concurrent use of <e10> drug1 </e10> and <e20> drug2 </e20> is contraindicated .
advise	digitalis : immediate - release <e12> drug1 </e12> ( such as digoxin ) should not be used with <e22> drug1 </e22> .
advise	as a consequence , in patients receiving <e10> drug1 </e10> concomitantly with <e22> drug1 _ sensitive _ drugs </e22> , discontinuation of the concomitant drug is advised .
advise	the concomitant use of <e10> drug1 </e10> and <e20> drug2 </e20> is not recommended .
advise	avoid the concomitant use of <e10> drug1 </e10> with other drugs that are metabolized by this isoenzyme ( e , g , , ketoconazole , itraconazole , nefazodone , <e20> drug2 </e20> , and rifampin ) .
advise	dose reduction of <e10> drug1 </e10> to 0 . 3 mg daily is recommended in combination with <e20> drug2 </e20> .
advise	<e10> drug1 </e10> should be used cautiously with <e21> drug2 </e21> and phenytoin .
advise	drugs whose absorption is varying with vardenafil : concomitant use of <e10> drug1 </e10> with <e20> drug1 </e20> is contraindicated .
advise	this interaction should be given consideration when co - administration of <e10> drug1 </e10> and <e20> drug2 </e20> is contemplated .
advise	patients should be cautioned to take <e10> drug1 </e10> concomitantly with <e22> drug2 </e22> .
advise	therefore , <e10> drug1 </e10> should not be used in combination with <e21> drug2 </e21> in patients receiving these agents concurrently .
advise	dose reduction of <e11> drug1 </e11> is not recommended in patients receiving oral <e20> drug2 </e20> or macrolides .
advise	therefore , co - administration of <e10> drug1 </e10> with <e20> drug2 </e20> is contraindicated .
advise	inhibitors of this enzyme , including <e10> drug1 </e10> , phenothiazines , and others of the arylamino / benzothiazepine _ type , should be cautiously administered to patients receiving <e20> drug2 </e20> .
advise	consequently , concomitant administration of <e10> drug1 </e10> and <e20> drug2 </e20> is contraindicated .
advise	therefore , co - administration of <e10> drug1 </e10> with other drugs that are extensively metabolized by this isozyme ( e , g , , inhibitors of cyp2d6 [ drug1 , indinavir , nelfinavir ] , cyp3a4 [ mitoxantrone ] , and certain protease inhibitors [ e , g , , clarithromycin ] ) , or that have a narrow therapeutic index ( e , g , , <e20> drug2 </e20> ) , should be approached with caution .
advise	caution should be exercised if <e10> drug1 </e10> is given concurrently with <e22> drug1 </e22> .
advise	in addition , drugs known to prolong the qt interval , such as <e10> drug1 </e10> , phenylephrine , and digoxin , should not be used in combination with <e20> drug1 </e20> .
advise	caution should be used if <e10> drug1 </e10> is administered with other drugs that prolong the qt interval ( e , g , , phenytoin , <e20> drug2 </e20> , and rifampin ) , or prolong the heart rate ( e , g , , cardiac _ gated _ rescue _ pulse ) , as these effects may increase the qtc interval and decrease cardiac output .
advise	therefore , co - administration of <e10> drug1 </e10> and <e20> drug2 </e20> is not recommended .
advise	thus , concomitant administration of <e10> drug1 </e10> and <e20> drug2 </e20> is contraindicated .
advise	the daily dose of <e10> drug1 </e10> should not exceed # mg when coadministered with other drugs that affect cardiac function ( e , g , , <e20> drug2 </e20> , amikacin , rifampin , and gentamicin ) .
advise	the concomitant use of <e10> drug1 </e10> and <e22> drug2 </e22> is contraindicated .
advise	as with other drugs that increase the clearance of drug2 and that can potentially increase serum drug2 levels , the concomitant use of <e10> drug1 </e10> with <e22> drug2 </e22> is contraindicated .
advise	caution should be exercised when administering <e10> drug1 </e10> to patients receiving <e20> drug2 </e20> .
advise	the concomitant use of <e11> drug1 </e11> with <e22> drug2 </e22> is contraindicated .
advise	since drug1 is metabolized by cyp3a4 isoenzymes , caution should be used when <e11> drug1 </e11> is coadministered with cyp3a4 inhibitors , such as , efavirenz , nefazodone , and <e20> drug2 </e20> .
advise	caution should be used when administering <e11> drug1 </e11> to patients on <e22> drug2 </e22> therapy .
advise	caution should be exercised when <e10> drug1 </e10> is co - administered with other <e22> drug2 </e22> .
advise	therefore , co - administration of <e10> drug1 </e10> with other drugs that are metabolized by this isozyme ( e , g , , phenytoin , <e20> drug2 </e20> , diltiazem , terfenadine , and cimetidine ) should be approached with caution .
advise	caution should be used if <e11> drug1 </e11> is co - administered with agents that decrease blood glucose levels ( e , g , , diuretics , glycosides , hypoglycemic _ agents , <e20> drug2 </e20> ) because of the possible additive effects of drug1 with these agents .
advise	brovana , as with other <e10> drug1 </e10> , should be used with caution in patients receiving <e21> drug2 </e21> .
advise	therefore , the combined use of <e10> drug1 </e10> and <e20> drug2 </e20> is contraindicated .
advise	this interaction should be given consideration when <e10> drug1 </e10> is co - administered with <e20> drug2 </e20> .
advise	before taking <e10> drug1 </e10> , tell your doctor if you are taking another strong phenothiazine ( e , g , , fluvoxamine , divalproex , or seleverin ) or an intravenous <e22> drug2 </e22> ( e , g , , diazepam , zolpidem or triazolam ) .
advise	caution is advised when administering <e10> drug1 </e10> with other drugs that are metabolized by cyp2d6 including <e20> drug2 </e20> , itraconazole , erythromycin , clarithromycin , nefazadone , ritonavir , and saquinavir .
advise	consequently , it is recommended that <e11> drug1 </e11> not be used concomitantly with drugs that are metabolized by this isozyme , including drugs that are inhibitors of cyp3a4 ( e , g , , ketoconazole , itraconazole , erythromycin , clarithromycin , nefazadone , ritonavir , <e20> drug2 </e20> , nelfinavir , saquinavir , nelfinavir / skimproquine , saquinavir / sofavirenz ) , because of the potential for additive effects .
advise	when used concomitantly , <e10> drug1 </e10> and <e20> drug2 </e20> should not be coadministered .
advise	drugs that should not be coadministered with <e11> drug1 </e11> opioid _ analgesics : isometazin _ d , drug2 , nalbuphine antidepressants : fluoxetine , desipramine , paroxetine antihistamines : triazolam antimigraine _ aides : <e20> drug2 </e20> , ergot _ alkaloids ( tricyclic _ antidepressants )
advise	carbamazepine : drug1 <e10> drug1 </e10> dose may need to be reduced when co - administered with <e20> drug2 </e20> .
advise	drugs that may inhibit cyp3a4 activity ( e , g , , <e10> drug1 </e10> , itraconazole , itraconazole _ salicylate ) should be used with care in patients receiving <e20> drug2 </e20> .
advise	drug1 : isoniazid <e10> drug1 </e10> should be given with caution to patients receiving <e20> drug2 </e20> or other antiretroviral drugs , since they may increase serum drug2 levels .
advise	therefore , co - administration of <e11> drug1 </e11> with other strong cyp3a4 inhibitors ( e , g , , ketoconazole , drug2 , clarithromycin , <e20> drug2 </e20> , nefazodone , ritonavir , nelfinavir ) should be approached with caution .
advise	therefore , co - administration of <e11> drug1 </e11> with other drugs that are metabolized by this isozyme , including phenothiazines , other beta - blockers ( e , g , , <e20> drug2 </e20> , isosulfan ) , and type _ 1c _ antiarrhythmics ( e , g , , propafenone </e20> ) , should be approached with caution .
advise	this interaction should be given consideration when <e11> drug1 </e11> is administered concomitantly with <e20> drug2 </e20> .
advise	concomitant administration with <e10> drug1 </e10> and <e20> drug2 </e20> is contraindicated .
advise	therefore , concomitant use of <e10> drug1 </e10> and <e22> drug2 </e22> is not recommended .
advise	caution should be used when administering <e10> drug1 </e10> with other <e22> drug2 </e22> ( alprazolam , triazolam , midazolam , desipramine , salsalate ) , barbiturates ( propafenone , flecainide ) , sedatives ( midazolam ) , or anesthetics ( isoflurane ) .
advise	coadministration of <e10> drug1 </e10> and <e22> drug2 </e22> should be approached with caution , and it is recommended that the prothrombin time be closely monitored .
advise	concomitant administration with <e10> drug1 </e10> and <e20> drug2 </e20> is contraindicated .
advise	caution should be used when administering <e10> drug1 </e10> to patients receiving <e20> drug2 </e20> .
advise	for this reason , caution should be exercised when administering <e10> drug1 </e10> with other <e22> drug2 </e22> ( e , g , , erythromycin , clarithromycin , etc . ) , and it is recommended that those patients be observed closely for signs of erosions , or bleeding .
advise	thus , concomitant administration of <e10> drug1 </e10> with other antidepressants or other <e22> drug2 </e22> is not recommended .
advise	caution should be used when administering <e10> drug1 </e10> with benzodiazepines and <e20> drug2 </e20> as these agents may increase benzodiazepine concentrations and may increase plasma concentrations of the benzodiazepines .
advise	dosage adjustment of <e11> drug1 </e11> may be required when coadministered with <e20> drug2 </e20> .
advise	consequently , concomitant administration of <e10> drug1 </e10> with <e20> drug2 </e20> is contraindicated .
advise	coadministration of <e10> drug1 </e10> with <e20> drug2 </e20> is contraindicated .
advise	caution should be exercised if <e10> drug1 </e10> is administered concurrently with <e21> drug2 </e21> therapy , as the interactions may be additive .
advise	aspirin : <e11> drug1 </e11> should not be used in patients receiving <e22> drug2 </e22> therapy .
advise	therefore , when <e11> drug1 </e11> is used with <e22> drug2 </e22> , adjustments of the anticoagulant dosage should be made accordingly .
advise	therefore , extreme caution should be exercised when administering <e11> drug1 </e11> to patients receiving <e20> drug2 </e20> .
advise	the concomitant use of <e10> drug1 </e10> and <e20> drug2 </e20> is not recommended .
advise	caution should be exercised if <e10> drug1 </e10> is administered concomitantly with <e22> drug2 </e22> because of potential interactions with inhibitors of cyp3a4 and protease inhibitors ( e , g , , nelfinavir , saquinavir , drug1 ) .
advise	caution should be used when administering <e10> drug1 </e10> with other psychotropic _ agents ( e , g , , <e22> drug2 </e22> , risperidone , etc . ) because of potential interactions .
advise	therefore , co - administration of <e10> drug1 </e10> and certain other <e22> drug2 </e22> is not recommended .
advise	particular caution is advised in the administration of <e11> drug1 </e11> to patients receiving <e20> drug2 </e20> .
advise	nephrotoxic agents : caution should be exercised when <e11> drug1 </e11> is administered with agents that are also nephrotoxic ( e , g , , <e22> drug2 </e22> , clarithromycin ) or with agents that can prolong the qt interval ( e , g , , intravenous amiodarone ) .
advise	interactions with mixed _ agonist / antagonist _ opioid _ analgesics : caution is recommended when <e10> drug1 </e10> and <e21> drug2 </e21> are co - administered .
advise	nevertheless , caution is warranted when <e10> drug1 </e10> is administered concurrently with <e21> drug2 </e21> .
advise	<e10> drug1 </e10> should be used cautiously in patients taking <e22> drug2 </e22> or inhibitors of the α2 - adrenergic receptor ( e , g , , paroxetine , fluoxetine , sertraline ) .
advise	drugs that lower level of essential fatty acids : caution should be used when <e10> drug1 </e10> is given with other drugs that lower levels of essential fatty acids ( e , g , , , <e20> drug2 </e20> ) .
advise	concomitant administration of <e10> drug1 </e10> with <e20> drug2 </e20> is not recommended .
advise	should it be necessary to use <e10> drug1 </e10> in patients receiving <e20> drug2 </e20> , the dose of drug1 should be reduced to # mg per day .
advise	consequently , concomitant administration of <e10> drug1 </e10> with <e20> drug2 </e20> is contraindicated .
advise	drugs that should not be coadministered with <e11> drug1 </e11> antiarrhythmics : amiodarone ( diltiazem ) , quinidine antihistamines : hydroxyzine benzodiazepines ( drug2 , diazepam ) , <e20> drug2 </e20> , quinidine antimigraine : ergot _ derivatives ( dihydroergotamine ) , neostigmine antimycobacterial _ agents : vancomycin antiarrhythmics : amiodarone
advise	therefore , use of <e10> drug1 </e10> within # hours before or # hours after <e20> drug2 </e20> is contraindicated .
advise	nephrotoxic agents : caution should be used when <e10> drug1 </e10> is administered concurrently with agents that are strongly nephrotoxic ( e , g , , <e20> drug2 </e20> , phenobarbital ) or that inhibit angiotensin converting enzyme ( ace ) activity ( e , g , , diltiazem ) .
advise	caution should be used when administering <e10> drug1 </e10> to patients receiving <e20> drug1 </e20> concurrently .
advise	videx ( <e10> drug1 </e10> ) is not recommended to be used in combination with <e22> drug2 </e22> .
advise	therefore , co - administration of <e10> drug1 </e10> with other strong cyp3a4 inhibitors ( e , g , , ketoconazole , itraconazole , erythromycin , <e20> drug2 </e20> , nelfinavir , ritonavir , saquinavir ) should be approached with caution .
advise	dose adjustment of <e10> drug1 </e10> is recommended when used with other <e22> drug2 </e22> _ drugs .
advise	when used concomitantly , <e10> drug1 </e10> and <e20> drug2 </e20> should be given with caution .
advise	inhibitors of this type of cyp3a4 isozyme , such as <e10> drug1 </e10> and certain protease inhibitors ( e , g , , nelfinavir , ritonavir , etc ) , should be cautiously administered with <e21> drug2 </e21> because they may increase the plasma concentrations of drug2 .
advise	drugs that should not be coadministered with <e11> drug1 </e11> drugs that should not be coadministered with coadministered with drug1 antidepressants - <e20> drug2 </e20> antimigraine agents - phenytoin , carbamazepine , and triazolam antimigraine - benzodiazepines antimigraine - phenytoin antimigraine - phenobarbital antimigraine - triazolam antimigraine - triazolam antimigraine - ergot _ derivatives antimigraine - ergotamine antimigraine - meclofenamate antimigraine - morphine antimigraine - terfenadine antimigraine - terfenadine antimigraine - tramadol antimigraine - tricyclic _ antidepressants antimigraine - ven
advise	it is recommended that no <e10> drug1 </e10> be used with <e20> drug2 </e20> .
advise	caution should be used if <e10> drug1 </e10> is administered concurrently with <e20> drug2 </e20> .
advise	consequently , concomitant administration of <e11> drug1 </e11> and <e20> drug2 </e20> is contraindicated .
advise	caution should be used when <e11> drug1 </e11> is co - administered with agents that are inhibitors of the human cyp2d6 enzymatic activity ( e , g , , ketoconazole , clarithromycin , <e20> drug2 </e20> , etc ) .
advise	drug1 : <e12> drug1 </e12> is contraindicated in patients receiving <e21> drug2 </e21> .
advise	refer to the package insert for <e10> drug1 </e10> before use of this or any other <e22> drug2 </e22> .
advise	however , caution should be exercised when <e11> drug1 </e11> is given concomitantly with drugs that affect the adrenergic system ( e , g , , <e20> drug2 </e20> , methylprednisolone , methimazole , phenobarbital ) or the central nervous system ( e , g , , antidepressants , fluoxetine , paroxetine , sertraline ) .
advise	caution should be exercised when administering <e10> drug1 </e10> to patients receiving <e22> drug2 </e22> .
advise	drugs that should not be coadministered with <e11> drug1 </e11> : antimycobacterial _ agents : drug2 ( <e20> drug2 </e20> ) , rifampin ( rifampin </e20> ) , tobramycin ( tobramycin </e20> ) , gentamicin ( gentamicin </e20> ) , ciprofloxacin ( tobramycin </e20> ) , and clarithromycin ( clarithromycin </e20> ) .
advise	because of the potential of potentiating drug effects , the combination of <e10> drug1 </e10> and <e20> drug2 </e20> is contraindicated .
advise	therefore , co - administration of <e10> drug1 </e10> and <e20> drug2 </e20> is not recommended .
advise	however , prudent medical management is advised when <e11> drug1 </e11> is administered concurrently with <e22> drug2 </e22> .
advise	coadministration of <e10> drug1 </e10> with <e20> drug2 </e20> is not recommended .
advise	therefore , co - administration of <e10> drug1 </e10> with other drugs that are metabolized by this isozyme , including antidepressants ( tricyclic _ antidepressants [ tcas ] ) , phenothiazines ( type _ 1 _ antiarrhythmics [ thins ] , such as propafenone , flecainide ) , and type _ 2 _ antiarrhythmics ( propafenone , flecainide ) , or with drugs that increase cyp3a4 activity ( <e20> drug2 </e20> ) , should be approached with caution .
advise	caution should be used when administering <e11> drug1 </e11> with other <e22> drug2 </e22> or agents known to prolong the qtc interval ( e , g , , certain drugs of the benzodiazepine and triazolam classes ) .
advise	caution should be exercised when administering <e11> drug1 </e11> to patients receiving <e20> drug2 </e20> .
advise	co - administration of <e11> drug1 </e11> with drugs that inhibit g - protein - coupled receptors ( e , g , , aspirin , <e20> drug2 </e20> , ergot _ alkaloids , tricyclic _ antidepressants ) should be approached with caution .
advise	coadministration of <e10> drug1 </e10> with <e20> drug2 </e20> is not recommended .
advise	caution should be exercised if <e10> drug1 </e10> is given concomitantly with <e20> drug2 </e20> .
advise	the consumption of <e10> drug1 </e10> with other drugs of the central nervous system such as phenothiazines , carbamazepine , and <e22> drug2 </e22> is not recommended .
advise	when concomitant treatment with <e10> drug1 </e10> and <e20> drug2 </e20> is to be initiated , drug2 to be administered at a rate of 0 . 4 mg · kg ( - 1 ) · day ( - 1 ) .
advise	therefore , co - administration of <e10> drug1 </e10> and other <e22> drug2 </e22> is not recommended .
advise	coadministration of <e10> drug1 </e10> with other <e22> drug2 </e22> ( e , g , , heparin , digoxin , phenylephrine , and thrombin ) should be approached with caution , and patients on these medications should be observed closely for signs of anticoagulation depression .
advise	interactions with mixed _ agonist / antagonist _ opioid _ analgesics : the combined use of <e10> drug1 </e10> and <e21> drug2 </e21> is not recommended .
advise	dosage adjustment of <e11> drug1 </e11> may be necessary when coadministered with <e20> drug2 </e20> .
advise	nevertheless , caution is advised in administering <e10> drug1 </e10> to patients taking <e20> drug2 </e20> or other neuromuscular _ drugs .
advise	therefore , co - administration of <e10> drug1 </e10> with other drugs that are extensively metabolized by this isozyme ( e , g , , <e20> drug2 </e20> , clarithromycin , and voriconazole ) should be approached with caution .
advise	nonsteroidal _ antiinflammatory agents : <e11> drug1 </e11> should not be used with other <e22> drug2 </e22> .
advise	<e10> drug1 </e10> should be administered with extreme caution to patients who are already taking <e22> drug2 </e22> or other anticoagulants .
advise	dose adjustment of <e10> drug1 </e10> may be required when coadministered with <e20> drug2 </e20> .
advise	because of the potential of the sedative / hypnotic effects of drug1 , use of <e10> drug1 </e10> with other <e22> drug2 </e22> ( including diazepam , triazolam , etc . ) is not recommended .
advise	if concomitant treatment with <e10> drug1 </e10> and <e20> drug2 </e20> is clinically warranted , an appropriate titration of drug2 to a lower or no drug2 dose is recommended .
advise	therefore , the concomitant use of <e10> drug1 </e10> with <e20> drug2 </e20> is contraindicated .
advise	the potential effects of concomitant use of <e11> drug1 </e11> with drugs that are metabolized by this isozyme , including certain antidepressants , anxiolytics , and <e22> drug2 </e22> , should be considered .
advise	inhibitors of this isoenzyme ( e , g , , protease - inhibitors , <e10> drug1 </e10> , nelfinavir , ergot _ alkaloids , ritonavir , saquinavir , etc , ) should be cautiously co - administered with <e20> drug2 </e20> because of potential drug interactions .
advise	caution should be used if <e11> drug1 </e11> is used in combination with <e22> drug2 </e22> .
advise	concomitant use of <e10> drug1 </e10> and <e20> drug2 </e20> is not recommended .
advise	therefore , extreme caution should be exercised when administering <e11> drug1 </e11> to patients receiving <e20> drug2 </e20> .
advise	based on adult data , a gradual increase in dose of <e10> drug1 </e10> may be necessary during treatment with <e20> drug2 </e20> .
advise	<e11> drug1 </e11> should not be used with other <e22> drug2 </e22> or hypnotic _ drugs ( eg , propafenone , flecainide , isoflurane , quinidine ) .
advise	<e10> drug1 </e10> should be given with caution to patients taking phenytoin , <e21> drug2 </e21> , or other alkylating agents with cyp3a4 inhibitors in the immediate or early phase of therapy .
advise	co - administration of <e11> drug1 </e11> with drugs that have a narrow therapeutic index ( e , g , , cyclosporine , tacrolimus , <e20> drug2 </e20> , etc ) or low therapeutic index ( e , g , , phenytoin , ergot _ alkaloids , etc ) , should be approached with caution .
advise	when <e10> drug1 </e10> is coadministered with <e20> drug2 </e20> , the combination should be titrated appropriately .
advise	therefore , co - administration of <e11> drug1 </e11> with other <e22> drug2 </e22> is contraindicated .
advise	co - administration of <e11> drug1 </e11> with other drugs that inhibit the cyp3a4 enzyme , including antidepressants ( e , g , , nortriptyline , imipramine , paroxetine , fluoxetine , sertraline ) , or otherophylline ( e , g , , <e20> drug2 </e20> ) , should be approached with caution .
advise	<e10> drug1 </e10> should be administered with caution to patients being treated concurrently with <e22> drug2 </e22> or tobramycin .
advise	caution should be used when administering <e10> drug1 </e10> to patients receiving <e22> drug2 </e22> .
advise	therefore , co - administration of <e10> drug1 </e10> with other drugs that are extensively metabolized by this isozyme , including certain antidepressants ( tricyclic _ antidepressants [ tcas ] , such as nortriptyline [ <e21> drug2 </e21> ] and imipramine [ imipramine ] ) , and phenothiazines ( triazolam , diazepam ) , should be approached with caution .
advise	coadministration of <e11> drug1 </e11> with other <e20> drug2 </e20> ( e , g , , heparin , enoxacin , and clarithromycin ) should be approached with caution .
advise	drugs which require ≥ 50 % of plasma to be plasma free : concomitant use of <e10> drug1 </e10> and drugs which require ≥ 50 % of plasma to be plasma free ( eg , <e22> drug2 </e22> , amiodarone , and erythromycin ) should be approached with caution , and plasma concentrations of drug1 should be closely monitored .
advise	based on adult and pediatric experience with this combination , a dose adjustment of <e11> drug1 </e11> may be necessary when administered concurrently with <e20> drug2 </e20> .
advise	caution is therefore advised when administering <e10> drug1 </e10> to patients receiving <e22> drug2 </e22> .
advise	exert particular caution if <e11> drug1 </e11> is used concomitantly with other <e22> drug2 </e22> .
advise	therefore , co - administration of <e10> drug1 </e10> and other drugs that are metabolized by this isozyme ( e , g , , <e22> drug2 </e22> , opioids , phenothiazines , and type _ 1c _ antiarrhythmics ) should be approached with caution .
advise	<e11> drug1 </e11> should not be administered concurrently with <e20> drug2 </e20> or other potent cyp3a4 inhibitors such as , but not limited to , ketoconazole , itraconazole , and ergot _ alkaloids .
advise	coadministration of <e10> drug1 </e10> with <e20> drug2 </e20> is not recommended .
advise	because of drug1 ' s narrow therapeutic window , caution should be exercised when coadministering <e10> drug1 </e10> with other <e22> drug2 </e22> ( e , g , , heparin , disulfiram , cholestyramine ) or with certain protease _ inhibitors ( e , g , , theophylline ) .
advise	nephrotoxic agents : concomitant administration of <e10> drug1 </e10> with agents known to prolong the qt interval ( e , g , , <e22> drug2 </e22> , phenytoin , and nevirapine ) is contraindicated .
advise	inhibitors of this pathway , such as <e10> drug1 </e10> and lithium , should be given with caution in patients taking <e22> drug2 </e22> .
advise	therefore , nitroglycerin or <e10> drug1 </e10> should not be used in conjunction with <e22> drug2 </e22> .
advise	this interaction should be given consideration in patients receiving <e10> drug1 </e10> concurrently with <e22> drug2 </e22> .
advise	it is recommended that <e11> drug1 </e11> not be used with agents known to depress renal function , such as <e22> drug2 </e22> , nephrotoxic drugs , or medications known to prolong the qtc interval ( e , g , , certain antidepressants , carbamazepine , and phenytoin ) .
advise	if concomitant treatment with <e11> drug1 </e11> and <e20> drug2 </e20> is clinically warranted , use of a lower dose of drug1 is recommended .
advise	concomitant administration of <e10> drug1 </e10> with <e20> drug2 </e20> is contraindicated .
advise	the concomitant use of <e10> drug1 </e10> and <e20> drug2 </e20> is not recommended .
advise	if intravenous <e10> drug1 </e10> is used in combination with <e20> drug2 </e20> , the dose of drug1 should be reduced .
advise	this interaction should be given consideration when <e11> drug1 </e11> is co - administered with other drugs known to prolong the qtc interval ( e , g , , phenytoin , flecainide , <e20> drug2 </e20> , ritonavir , etc )
advise	because prostaglandins play a role in the pathogenesis of atopic dermatitis , the co - administration of <e10> drug1 </e10> and <e20> drug2 </e20> is contraindicated .
advise	therefore you may need to increase the dose of <e11> drug1 </e11> by # mg if <e20> drug2 </e20> is used instead of rifampin .
advise	<e10> drug1 </e10> should not be used with other antidepressants ( <e20> drug2 </e20> , nortriptyline , paroxetine , fluoxetine , sertraline ) , benzodiazepines ( diazepam ) , and type _ 1c _ antiarrhythmics ( propafenone , flecainide ) , as they may increase blood pressure .
advise	caution should be used when <e11> drug1 </e11> is administered concurrently with <e22> drug2 </e22> .
advise	therefore concomitant administration of <e10> drug1 </e10> and <e22> drug2 </e22> is contraindicated .
advise	drugs that lower hmg - coa _ reductase activity : <e10> drug1 </e10> should not be used in patients receiving <e20> drug2 </e20> therapy because drug1 has been reported to lower hepatic lipase activity .
advise	consequently , concomitant administration of <e10> drug1 </e10> and <e20> drug2 </e20> is contraindicated .
advise	this interaction should be taken into consideration in patients taking <e10> drug1 </e10> concomitantly with <e20> drug2 </e20> .
advise	drugs that should not be coadministered with <e10> drug1 </e10> antimigraine agents : tricyclic _ antidepressants ( tcas ) , nortriptyline ( ntp ) , fluoxetine ( flx ) , paroxetine ( parox ) , desipramine ( disapt ) , sertraline ( synthetic ) , fluvoxamine ( fluox ) , <e20> drug2 </e20> ( excit ) , paroxetine ( purpose ) , nortriptyline ( norutil ) , fluvoxamine ( fluox ) , paroxetine ( purpose ) , nortriptyline _ hcl ( norutil ) , sertraline ( synthetic ) , fluvoxamine ( fluox )
advise	caution should be used when administering <e10> drug1 </e10> to patients receiving <e20> drug2 </e20> .
advise	it is suggested that co - administration of <e10> drug1 </e10> with other <e22> drug2 </e22> ( e , g , , diltiazem , desvenlafaxine , paroxetine , fluoxetine , sertraline , sertraline ) should be approached with caution .
advise	because prostaglandina play an important role in the pathogenesis of prostaglandin - dependent angina , it is recommended that <e11> drug1 </e11> not be used in combination with beta - blockers or <e22> drug2 </e22> .
advise	when concomitant administration of <e10> drug1 </e10> and <e20> drug2 </e20> is clinically warranted , an interval of at least # hours between the two drugs should be considered .
advise	caution should be used when administering <e10> drug1 </e10> to patients who are taking <e22> drug2 </e22> .
advise	caution is warranted when administering <e10> drug1 </e10> to patients receiving <e20> drug2 </e20> .
advise	if possible , <e12> drug1 </e12> should be withdrawn at least # hours before initiating or changing <e20> drug2 </e20> therapy .
advise	because of the potential for additive effects , use of <e10> drug1 </e10> with other <e22> drug2 </e22> ( e , g , , fluvoxamine , paroxetine , fluvoxamine _ hcl , fluvoxamine , sertraline , escitalopram , citalopram , desipramine ) should be approached with caution .
advise	dose adjustment of <e10> drug1 </e10> to less than # mg / day is not recommended in patients receiving <e20> drug2 </e20> .
advise	exert particular caution when <e11> drug1 </e11> is administered to patients receiving other <e22> drug2 </e22> ( eg , phenothiazines , carbamazepine , and verapamil ) .
advise	when initiating a <e11> drug1 </e11> , the concomitant administration of <e22> drug2 </e22> is not recommended .
advise	nephrotoxic agents : concomitant treatment with <e11> drug1 </e11> and agents that are potent inhibitors of glomerular filtration ( e , g , , diuretics , <e20> drug2 </e20> , nsaids ) should be avoided .
advise	the concomitant use of <e10> drug1 </e10> with other <e22> drug2 </e22> is contraindicated .
advise	nephrotoxic agents : coadministration of <e10> drug1 </e10> with <e20> drug2 </e20> is contraindicated .
advise	drug1 : isoniazid : <e10> drug1 </e10> dose should not exceed the recommended patient dose in patients receiving <e20> drug2 </e20> .
advise	if <e10> drug1 </e10> is used concomitantly with <e21> drug2 </e21> or ritonavir , the dose of drug1 should be reduced by 50 % or discontinued .
advise	routine administration of <e10> drug1 </e10> within # days of initiating <e20> drug2 </e20> is contraindicated .
advise	additionally , <e11> drug1 </e11> should be used cautiously with other <e20> drug2 </e20> , including some protease _ inhibitors , phenytoin , warfarin , and diflunisal .
advise	drugs that induce hypoglycemia and should be taken cautiously in patients on <e10> drug1 </e10> therapy include phenytoin , glimepiride , ketoconazole , ritonavir , <e20> drug2 </e20> , indinavir , nelfinavir , ritonavir , drug2 , telithromycin and tobramycin .
advise	consequently , it is recommended that <e11> drug1 </e11> not be used in combination with other <e20> drug2 </e20> , and that the coadministration of drugs that are extensively metabolized by this isozyme be avoided .
advise	it is recommended that <e10> drug1 </e10> not be used in conjunction with other <e20> drug2 </e20> .
advise	consequently , concomitant administration of <e10> drug1 </e10> with <e20> drug2 </e20> is contraindicated .
advise	cyclosporine , <e10> drug1 </e10> and <e20> drug2 </e20> should not be administered together .
advise	<e11> drug1 </e11> should not be used in combination with other drugs that are substrates for the cyp3a4 isoenzyme , such as <e20> drug2 </e20> , fluconazole , and itraconazole .
advise	<e10> drug1 </e10> should not be given with other ssris ( eg , <e22> drug2 </e22> ) or with other non - peptide _ based _ antidepressants ( eg , fluoxetine or citalopram ) .
advise	consequently , concomitant administration of <e10> drug1 </e10> and <e20> drug2 </e20> is contraindicated .
advise	caution is advised in the administration of <e10> drug1 </e10> and <e22> drug2 </e22> .
advise	concomitant administration of <e10> drug1 </e10> and <e20> drug2 </e20> is not recommended .
advise	drug1 : <e12> drug1 </e12> should not be administered to patients who are taking <e22> drug2 </e22> ( e , g , , warfarin , thromboprophylaxis , prothrombin ) .
advise	coadministration of <e10> drug1 </e10> and <e20> drug2 </e20> is not recommended .
advise	drugs that should not be coadministered with <e10> drug1 </e10> : imidazole _ diuretics , amphotericin _ b ( particularly in combination with <e22> drug2 </e22> ) , phenytoin , or thioridazine
advise	therefore , such combined therapy should be avoided in patients receiving <e11> drug1 </e11> and <e22> drug2 </e22> concurrently .
advise	close supervision and careful adjustment of dosing are required when <e12> drug1 </e12> is used in combination with <e21> drug2 </e21> .
advise	<e11> drug1 </e11> should be used with caution in patients receiving <e20> drug2 </e20> and other neuromuscular _ blocking agents .
advise	consequently , concomitant administration of <e10> drug1 </e10> and <e20> drug2 </e20> is contraindicated .
advise	for example , when <e10> drug1 </e10> is added to <e22> drug2 </e22> or methotrexate , the doses of both should be adjusted accordingly .
advise	this time window for oral <e10> drug1 </e10> administration should be considered when initiating or adjusting <e21> drug2 </e21> .
advise	therefore , when using <e10> drug1 </e10> with other <e20> drug2 </e20> ( such as isoflurane , halothane , midazolam , terfenadine , and thioridazine ) , it is recommended to use the lowest possible dose of the anesthetic .
advise	therefore , co - administration of <e10> drug1 </e10> with other classes of <e22> drug2 </e22> _ drugs ( e , g , , itraconazole , cisapride , sirolimus , or foscarnet ) should be approached with caution .
advise	therefore , close monitoring of patients with <e10> drug1 </e10> within 72 hours of starting treatment with <e21> drug2 </e21> is recommended .
advise	close supervision and monitoring of patients on <e11> drug1 </e11> and <e22> drug2 </e22> are required .
advise	warfarin : anticoagulant therapy should not be discontinued when <e10> drug1 </e10> is coadministered with <e21> drug2 </e21> .
advise	therefore , cyp3a4 substrates of this isoenzyme , including <e10> drug1 </e10> , phenytoin , phenobarbital , and fluvoxamine , should be administered with caution in patients receiving <e21> drug2 </e21> .
advise	caution should be exercised when administering <e10> drug1 </e10> to patients receiving <e22> drug2 </e22> .
advise	particular caution is warranted when <e11> drug1 </e11> is administered concurrently with <e22> drug2 </e22> .
advise	coadministration of <e10> drug1 </e10> with other <e22> drug2 </e22> ( e , g , , ketoconazole , clarithromycin , nefazodone , etc , ) is contraindicated .
advise	however , prudent medical therapy with <e10> drug1 </e10> is not indicated in patients receiving <e21> drug2 </e21> .
advise	this time window is recommended when administering <e10> drug1 </e10> to hiv - infected patients concurrently with <e22> drug2 </e22> .
advise	<e10> drug1 </e10> should not be administered with other drugs that have been shown to prolong the qt interval ( e , g , , <e20> drug2 </e20> , amphotericin _ b , itraconazole , erythromycin , etc )
advise	therefore , it is recommended that <e10> drug1 </e10> not be co - administered with other <e22> drug2 </e22> .
advise	use lowest possible dose and time of administration when <e10> drug1 </e10> is used with other <e22> drug2 </e22> .
advise	caution should be used when administering <e11> drug1 </e11> with cyp3a4 substrates , such as certain <e20> drug2 </e20> and protease _ inhibitors ( e , g , , , certain cyp3a4 substrates ) .
advise	diazepam : the concomitant use of <e10> drug1 </e10> and <e21> drug2 </e21> is not recommended .
advise	therefore , concurrent use of <e10> drug1 </e10> and <e20> drug2 </e20> is contraindicated .
advise	serum drug2 levels should be monitored frequently if <e10> drug1 </e10> is administered concomitantly with <e20> drug2 </e20> .
advise	<e10> drug1 </e10> should be used with caution in patients receiving <e20> drug2 </e20> and / or erythromycin .
advise	consequently , concomitant administration of <e10> drug1 </e10> with <e20> drug2 </e20> is contraindicated .
advise	anticoagulant therapy should be discontinued when <e10> drug1 </e10> is initiated in patients receiving <e21> drug2 </e21> .
advise	therefore , co - administration of <e10> drug1 </e10> and <e20> drug2 </e20> is not recommended .
advise	co - administration of <e11> drug1 </e11> with strong cyp3a4 inhibitors such as ketoconazole , itraconazole , nefazodone , and nelfinavir , or with <e22> drug2 </e22> such as fluvoxamine or paroxetine , should be approached with caution .
advise	therefore , cyp3a4 substrates <e11> drug1 </e11> should be co - administered with <e20> drug2 </e20> .
advise	consequently , concomitant administration of <e10> drug1 </e10> with drugs that are metabolized by this isozyme isoenzyme ( e , g , , <e20> drug1 </e20> , quinidine , isoniazid , etc , ) should be avoided .
advise	barbiturates and <e10> drug1 </e10> should be used cautiously in combination with <e21> drug2 </e21> .
advise	therefore , co - administration of <e10> drug1 </e10> and <e20> drug2 </e20> is not recommended .
advise	dose adjustment of <e10> drug1 </e10> may be required in patients receiving concomitant <e22> drug2 </e22> therapy .
advise	methotrexate : caution should be exercised when administering <e10> drug1 </e10> with <e20> drug2 </e20> .
advise	dosage adjustment of <e10> drug1 </e10> is recommended when co - administered with other <e22> drug2 </e22> .
advise	caution is therefore recommended when administering or taking <e10> drug1 </e10> with other drugs that are extensively metabolized by this isozyme , including certain <e22> drug2 </e22> , phenothiazines , carbamazepine , and type _ 1c _ antiarrhythmics ( e , g , , propafenone , flecainide ) .
advise	concomitant use of <e10> drug1 </e10> and <e20> drug2 </e20> is contraindicated .
advise	drugs that may inhibit phosphatase activity ( e , g , , erythromycin , <e10> drug1 </e10> , clarithromycin , ritonavir ) should not be used in combination with <e20> drug2 </e20> .
advise	concomitant use of <e10> drug1 </e10> and <e20> drug2 </e20> is not recommended .
advise	<e10> drug1 </e10> should not be used concomitantly with <e20> drug2 </e20> , ritonavir , saquinavir , indinavir , or zalcitabine .
advise	coadministration of <e10> drug1 </e10> with <e20> drug2 </e20> is not recommended .
advise	cyclosporine , tacrolimus and <e10> drug1 </e10> should be used cautiously in patients receiving <e21> drug2 </e21> , since they may increase the plasma concentration of catecholamines .
advise	coadministration of <e10> drug1 </e10> with other <e22> drug2 </e22> ( e , g , , nortriptyline , desipramine , imipramine , paroxetine ) should be approached with caution .
advise	caution should be exercised if <e10> drug1 </e10> is used with other antidepressants , <e21> drug2 </e21> , or other agents known to prolong qtc interval .
advise	this interaction , which has not been evaluated in a general population of subjects , should be given consideration when <e11> drug1 </e11> is used in combination with <e22> drug2 </e22> .
advise	before taking <e10> drug1 </e10> , tell your doctor if you are taking another strong cyp3a4 inhibitor ( eg , itraconazole , clarithromycin , <e20> drug2 </e20> ) or a cyp3a4 ( eg , itraconazole , nefazodone ) metabolite ( eg , alfentanil ) .
advise	caution should be exercised when administering <e10> drug1 </e10> to patients receiving <e22> drug2 </e22> or other calcium _ channel _ blockers .
advise	coadministration of <e10> drug1 </e10> with agents that prolong the qtc interval ( e , g , , <e20> drug2 </e20> and midazolam ) should be approached with caution .
advise	before taking <e10> drug1 </e10> , tell your doctor if you are taking any of the following medicines : aspirin or other nonsteroidal anti - inflammatory drugs ( eg , naproxen or <e20> drug2 </e20> ) ;
advise	consequently , concomitant administration of <e10> drug1 </e10> with other <e20> drug2 </e20> is contraindicated .
advise	therefore , co - administration of <e11> drug1 </e11> with other cns _ depressants ( e , g , , phenothiazines , <e20> drug2 </e20> , or aripiprazole ) should be approached with caution .
advise	<e11> drug1 </e11> should not be administered with other drugs that are metabolized by this isozyme ( e , g , , ketoconazole , <e20> drug2 </e20> , clarithromycin , nefazadone , ritonavir , nelfinavir , nelfinavir _ resinato , saquinavir , saquinavir _ hcl , telithromycin ) .
advise	co - administration of <e11> drug1 </e11> with other drugs that are metabolized by this isozyme ( e , g , , ketoconazole , <e20> drug2 </e20> , clarithromycin , nefazodone , nefazadone , troleandomycin , voriconazole , and telithromycin ) should be approached with caution .
advise	concomitant administration of <e11> drug1 </e11> with <e22> drug2 </e22> should be approached with caution , and additional observation of patients receiving these agents is recommended .
advise	consequently , it is recommended that <e10> drug1 </e10> not be administered concomitantly with <e20> drug2 </e20> or other drugs that are metabolized by this isozyme , such as dihydroergotamine , methysergide , quinidine , or thioridazine .
advise	before taking <e10> drug1 </e10> , tell your doctor if you are taking any of the following medicines : antibiotics ( especially <e20> drug2 </e20> ) , strongides ( especially phenytoin and ergot _ alkaloids </e20> ) , beta - blockers ( especially amiodarone ) , magnesium _ containing antacids ( especially calcium _ antacids ) , antiarrhythmics ( especially propafenone and flecainide ) , or steroid _ drugs ( like budesonide ) .
advise	coadministration of <e10> drug1 </e10> and <e22> drug2 </e22> should be avoided .
advise	nevertheless , caution is advised when administering <e11> drug1 </e11> with other <e22> drug2 </e22> such as halogenated _ nitrates , anesthetics , sedatives , phenothiazines , or anesthetics .
advise	therefore , co - administration of <e10> drug1 </e10> and <e20> drug2 </e20> is not recommended .
advise	drugs that should not be coadministered with <e11> drug1 </e11> oral antimigraine agents : benzodiazepines ( <e20> drug2 </e20> , zolpidem ) , non - analgesic _ antihypertensives ( bisoprolol , indomethacin ) , and phenytoin .
advise	drugs that should not be coadministered with <e11> drug1 </e11> agents : agents that should not be administered with <e20> drug1 </e20> include agents with antipyretic or sedative activity , agents with an intravenous metabolite that is toxic to the kidney ( e , g , , cisapride ) , agents with an alpha1 - blocking effect ( e , g , , fluvoxamine ) , agents with a sirolimus - like action ( e , g , , cilazapril ) , and agents that decrease erythrocyte magnesium levels ( e , g , , amiodarone ) .
advise	therefore , co - administration of <e11> drug1 </e11> with other strong cyp3a4 inhibitors ( e , g , , ketoconazole , itraconazole , clarithromycin , <e20> drug2 </e20> , nefazadone , nelfinavir ) should be approached with caution .
advise	if treatment with <e10> drug1 </e10> is indicated , dosage reduction is recommended when starting <e21> drug2 </e21> therapy with a lower initial dose .
advise	monoamine _ oxidase _ inhibitors and tricyclic _ antidepressants : <e11> drug1 </e11> should be administered with caution to patients receiving antidepressants or other sympathomimetic _ drugs that contain <e22> drug2 </e22> .
advise	the daily dose of <e10> drug1 </e10> should not exceed 2 mg and should not be increased beyond this dose , except in patients taking <e20> drug2 </e20> .
advise	<e11> drug1 </e11> should not be administered to patients receiving <e22> drug2 </e22> ( e , g , , phenobarbital , dextran , and prothrombin ) .
advise	therefore , concomitant use of <e10> drug1 </e10> with other <e22> drug2 </e22> is contraindicated .
advise	for this reason , co - administration of <e11> drug1 </e11> with other antidepressants ( tricyclic _ antidepressants , monoamine _ oxidase _ inhibitors , <e20> drug2 </e20> , and sertraline ) should be approached with caution .
advise	in patients receiving <e10> drug1 </e10> with <e20> drug2 </e20> , a dose reduction of drug1 from 50 to 25 mg daily should be considered .
advise	caution should be used if <e11> drug1 </e11> is administered to a patient taking <e20> drug2 </e20> .
advise	based on adult experience , <e10> drug1 </e10> should be administered with caution to patients who have taken <e20> drug2 </e20> .
advise	therefore , concomitant use of <e10> drug1 </e10> and <e22> drug2 </e22> is contraindicated .
advise	therefore , co - administration of <e10> drug1 </e10> with <e20> drug2 </e20> is contraindicated .
advise	as a consequence , <e10> drug1 </e10> should not be administered to patients receiving or treated with <e21> drug2 </e21> , a drug with a narrow therapeutic index , and the concomitant use of drug1 should be approached with caution .
advise	for example , when <e10> drug1 </e10> is administered with other <e22> drug2 </e22> ( e , g , , heparin , phenylephrine , and other anti - coagulants ) , coagulation parameters and the action of the anesthetic should be closely monitored .
advise	drugs that should not be coadministered with <e11> drug1 </e11> antibiotics : ampicillin , gentamicin , netilmicin , <e20> drug2 </e20> , diflunisal , nafcillinamide antimycobacterial drugs : ergot _ derivatives antimycobacterial x _ reagents : penicillamine , rifampin antimycobacterial not so antimycobacterial drugs : itraconazole , terfenadine antimycobacterial quinones : rifampin antimycobacterial disketides : rifampin , gentamicin antimycobacterial sepinones : rifampin , gentamicin antimycobacterial tetracyclines : rifampin antimycobacterial disketides : gentamicin antimy
advise	inhibitors of this enzyme , including phenytoin , rifampin , <e10> drug1 </e10> , nefazodone , and ergot _ alkaloids , should be used cautiously in patients receiving <e20> drug2 </e20> .
advise	if treatment with <e10> drug1 </e10> is required , the dose should be reduced to <e20> drug2 </e20> and cautiously titrated .
advise	caution should be used if <e10> drug1 </e10> is administered concurrently with <e22> drug2 </e22> .
advise	concomitant administration of <e10> drug1 </e10> with <e20> drug2 </e20> is contraindicated .
advise	this interaction should be given consideration in patients receiving <e10> drug1 </e10> concomitantly with <e21> drug2 </e21> .
advise	coadministration of <e10> drug1 </e10> with <e22> drug2 </e22> is not recommended .
advise	additionally , <e11> drug1 </e11> should be used cautiously with patients receiving strong cyp3a4 inhibitors such as amiodarone , clarithromycin , <e20> drug2 </e20> , nelfinavir , saquinavir , telithromycin , nefazodone , nelfinavir , and nelfinavir _ hcl ( zebeta ) .
advise	based on these data , it is recommended that <e10> drug1 </e10> not be taken concurrently with <e21> drug2 </e21> or its derivatives .
advise	if it is necessary to reduce the dose of <e10> drug1 </e10> , then it is recommended to start the reduction when the first dose of <e20> drug2 </e20> is reduced by approximately 80 % .
advise	caution should be exercised when <e10> drug1 </e10> is administered concomitantly with other <e22> drug2 </e22> .
advise	<e10> drug1 </e10> should not be given with other <e20> drug2 </e20> antibiotics .
advise	concomitant administration with <e10> drug1 </e10> and <e20> drug2 </e20> is not recommended .
advise	accordingly , <e10> drug1 </e10> dose should be reduced to one - third of the usual dosage when co - administered with <e21> drug2 </e21> .
advise	caution should be exercised if <e10> drug1 </e10> is administered concomitantly with <e20> drug2 </e20> .
advise	although specific drug interaction studies have not been conducted with <e11> drug1 </e11> , the possibility of an additive or potentiating effect with <e20> drug2 </e20> should be considered .
advise	monoamine _ oxidase _ inhibitors and tricyclic _ antidepressants : concomitant use of <e10> drug1 </e10> with <e20> drug2 </e20> is contraindicated .
advise	caution should be exercised if <e10> drug1 </e10> is administered concurrently with <e22> drug2 </e22> .
advise	<e10> drug1 </e10> should not be given to patients on <e22> drug2 </e22> ( such as warfarin ) who have received any treatment with the above drugs in the preceding 3 months .
advise	if concomitant treatment with <e10> drug1 </e10> and <e20> drug2 </e20> is clinically warranted , a reduction in the drug2 dosage should be considered .
advise	routine administration of <e10> drug1 </e10> with <e20> drug2 </e20> is contraindicated .
advise	therefore , <e11> drug1 </e11> should be administered with caution to patients receiving <e20> drug2 </e20> or other inhibitors of cyp3a4 activity .
advise	coadministration of <e10> drug1 </e10> with other <e22> drug2 </e22> ( e , g , , ergot _ alkaloids , dihydroergotamine , nifedipine ) is not recommended because of the potential additive effects on cardiac function .
advise	also , due to the potential for this interaction to increase drug concentrations in plasma , co - administration of <e11> drug1 </e11> with other agents known to increase plasma drug levels ( e , g , , <e20> drug2 </e20> and itraconazole ) is contraindicated .
advise	therefore , co - administration of <e11> drug1 </e11> with other drugs that are metabolized by this isozyme ( e , g , , antidepressants , antipsychotics , <e20> drug2 </e20> , type _ 1c _ antiarrhythmics , and others ) should be approached with caution .
advise	concomitant use of <e10> drug1 </e10> and <e20> drug2 </e20> is not recommended .
advise	therefore , use of <e10> drug1 </e10> with <e20> drug2 </e20> is contraindicated .
advise	the concomitant use of <e11> drug1 </e11> with other <e20> drug2 </e20> ( such as thrombin inhibitors , warfarin , or fibrates ) is contraindicated .
advise	this interaction should be given consideration in patients taking <e10> drug1 </e10> concomitantly with <e20> drug2 </e20> .
advise	close supervision and close monitoring of cyp3a4 substrates and <e10> drug1 </e10> are recommended when coadministered with <e21> drug2 </e21> .
advise	inhibitors of this isoenzyme ( e , g , , ketoconazole , <e10> drug1 </e10> , and drug1 protease ) should be avoided during therapy with <e21> drug2 </e21> .
advise	digitalis : immediate discontinuation of the <e12> drug1 </e12> dose should be considered when coadministered with <e20> drug2 </e20> .
advise	it is , therefore , recommended that <e11> drug1 </e11> not be used concurrently with <e20> drug2 </e20> or hmg - coa _ reductase _ inhibitors .
advise	<e11> drug1 </e11> should not be administered with <e20> drug2 </e20> , phenytoin , or other phenothiazines .
advise	exert particular caution when <e10> drug1 </e10> is given with other <e22> drug2 </e22> , and particularly with thrombin - antithrombin or warfarin .
advise	therefore , co - administration of <e10> drug1 </e10> and other strong cyp3a4 inhibitors such as , but not limited to , ketoconazole , itraconazole , nefazodone , troleandomycin , erythromycin , clarithromycin , <e20> drug2 </e20> , telithromycin , drug2 , saquinavir , nelfinavir , nelfinavir _ resistance _ testosterone , telithromycin _ resistance _ testosterone , and ergot _ alkaloids ( ergotamine , dihydroergotamine ) is contraindicated .
advise	consequently , concomitant administration of <e10> drug1 </e10> and <e20> drug2 </e20> is not recommended .
advise	the daily dose of <e11> drug1 </e11> should not exceed # mg in a 24 - hour period when administered with any of the <e22> drug2 </e22> .
advise	<e10> drug1 </e10> should be administered with caution to patients receiving <e20> drug2 </e20> or itraconazole .
advise	thus , when <e12> drug1 </e12> are administered concomitantly with <e22> drug2 </e22> ( e , g , , granulocyte - colony - stimulating factor [ g - csf ] ) , a reduction in the dosage of these agents may be required .
advise	it is suggested that patients receiving <e10> drug1 </e10> dose - dependently for longer than 1 h should not be co - treated with <e20> drug2 </e20> .
advise	before taking <e10> drug1 </e10> , tell your doctor if you are taking any of the following medicines : aspirin or another salicylate such as magnesium / choline _ salicylate ; magnesium _ salicylate ; <e21> drug2 </e21> ; drug1 ; or diltiazem .
advise	brovana , as with other <e12> drug1 </e12> , should be titrated cautiously in patients receiving <e21> drug2 </e21> .
advise	therefore , patients without an anticoagulant agent should be carefully monitored when <e10> drug1 </e10> is added to <e20> drug2 </e20> therapy .
advise	nevertheless , caution is advised when <e10> drug1 </e10> is co - administered with other <e20> drug2 </e20> or antidepressants .
advise	caution should be exercised if <e10> drug1 </e10> is administered concomitantly with <e20> drug1 </e20> , as drug1 may reduce the antifungal efficacy of drug1 .
advise	consequently , concomitant administration of <e10> drug1 </e10> and <e22> drug2 </e22> is not recommended .
advise	coadministration of <e10> drug1 </e10> and other strong cyp3a4 inhibitors ( e , g , , ketoconazole , nefazodone , clarithromycin , <e20> drug2 </e20> , ritonavir , telithromycin ) should be approached with caution , since the clinical effects of these drugs may be additive .
advise	because of drug1 - associated hypercalcemia , it is recommended that <e10> drug1 </e10> not be used concomitantly with <e20> drug2 </e20> , calcium _ channel _ blockers , or β - adrenergic _ agonists .
advise	dose reduction of <e10> drug1 </e10> may be required in patients receiving <e21> drug2 </e21> .
advise	therefore , such combined therapy should be approached with caution in patients receiving <e10> drug1 </e10> and <e20> drug2 </e20> .
advise	concomitant use of <e10> drug1 </e10> and <e20> drug2 </e20> is not recommended .
advise	other 5 - ht1b / 1d _ agonists concomitant administration of <e10> drug1 </e10> with <e22> drug2 </e22> is contraindicated .
advise	a dose increase of <e10> drug1 </e10> to # mg twice daily is recommended for patients receiving <e20> drug2 </e20> concurrently .
advise	dose adjustment of <e10> drug1 </e10> in patients taking <e22> drug2 </e22> is not recommended .
advise	<e10> drug1 </e10> dose should be reduced if a <e20> drug2 </e20> dose is to be administered concomitantly .
advise	caution should be exercised when <e11> drug1 </e11> is administered concomitantly with <e22> drug1 </e22> .
advise	therefore , co - administration of <e10> drug1 </e10> with psychotropic _ agents ( <e22> drug2 </e22> ) such as , bupropion , paroxetine , fluoxetine , citalopram , fluvoxamine , fluvoxamine _ sulfate , paroxetine , sertraline , fluvoxamine _ dose and escitalopram should be approached with caution and may require dosage reduction / termination of treatment .
advise	inhibitors of this mechanism ( e , g , , ketoconazole , <e10> drug1 </e10> , voriconazole , and amphotericin _ b ) should be cautiously administered to patients receiving <e21> drug2 </e21> therapy .
advise	therefore , co - administration of <e11> drug1 </e11> with other antidepressants ( , amitriptyline , and <e20> drug2 </e20> ) should be approached with caution .
advise	although it has not been established if reduced cyp3a4 activity results in a change in concomitant drugs , it is recommended that <e11> drug1 </e11> be used with caution in patients receiving <e20> drug2 </e20> or clarithromycin .
advise	additionally , <e11> drug1 </e11> should be avoided in patients taking <e20> drug2 </e20> or other strong cyp3a4 inhibitors such as atazanavir , clarithromycin , indinavir , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
advise	this interaction should be given consideration in patients taking <e11> drug1 </e11> concomitantly with <e20> drug2 </e20> .
advise	caution should be exercised when administering <e10> drug1 </e10> to patients taking <e20> drug2 </e20> .
advise	caution should be exercised when <e11> drug1 </e11> is administered concomitantly with <e20> drug2 </e20> .
advise	it may be necessary to decrease or discontinue <e10> drug1 </e10> dose in patients taking <e22> drug2 </e22> concurrently .
advise	therefore , cyp3a4 substrates , including <e10> drug1 </e10> , drug1 _ hydrochloride , and drug1 _ sodium , should be administered with caution to patients receiving <e21> drug2 </e21> .
advise	however , as with other drugs , dose adjustment of <e10> drug1 </e10> is required in patients taking concomitant <e20> drug2 </e20> .
advise	it is suggested that <e10> drug1 </e10> should not be administered with other nsaids such as <e20> drug2 </e20> .
advise	<e11> drug1 </e11> should not be taken at the same time with other <e22> drug2 </e22> ( e , g , , alcohol , barbiturates , phenobarbital , pentobarbital ) .
advise	<e10> drug1 </e10> should be used cautiously with medications that are known to depress serotonin levels such as <e21> drug2 </e21> ( tcas ) , nortriptyline , and fluvoxamine .
advise	<e11> drug1 </e11> should not be used in combination with <e22> drug2 </e22> or agents known to alter the gastrointestinal ( gi ) tract such as antacids , or laxatives such as phenylhydrazine , cimetidine , or tricyclic _ antidepressants .
advise	<e11> drug1 </e11> should not be used in combination with other <e22> drug2 </e22> or potent inhibitors of the mammalian target of rapamycin ( mtor ) .
advise	other 5 - ht1b / 1d _ agonists concomitant use of <e11> drug1 </e11> with <e22> drug2 </e22> is not recommended
advise	the iv <e10> drug1 </e10> dose should be increased if <e20> drug2 </e20> is added to the initial regimen .
advise	vitamin _ a and oral retinoids : <e11> drug1 </e11> should be given with care to patients receiving <e20> drug2 </e20> , since they may interfere with vitamin _ a and other retinoid absorption .
advise	the potential effects of concomitant treatment with <e10> drug1 </e10> and other strong cyp3a4 inhibitors ( e , g , , <e20> drug2 </e20> , nelfinavir , etc ) should be carefully considered .
advise	if the two medications are co - administered , it is recommended that <e10> drug1 </e10> be discontinued at least # hours before initiating <e20> drug2 </e20> therapy .
advise	diazepam : the following dose reduction is recommended when <e10> drug1 </e10> is co - administered with <e20> drug2 </e20> : a # mg dose reduction of drug1 may be required in patients receiving drug1 + drug2 .
advise	based on adult experience , <e11> drug1 </e11> should be used with caution in patients receiving high - dose corticosteroids or <e22> drug2 </e22> .
advise	inhibitors of this enzyme , such as clarithromycin , <e10> drug1 </e10> , and tobramycin , should be avoided in patients receiving <e20> drug2 </e20> .
advise	based on the findings of this study , caution should be used when <e11> drug1 </e11> is given concomitantly with <e22> drug2 </e22> .
advise	caution should be exercised if <e10> drug1 </e10> is used concomitantly with <e22> drug2 </e22> .
advise	caution should be used when <e10> drug1 </e10> is administered concurrently with <e21> drug2 </e21> .
advise	when concomitant administration of <e10> drug1 </e10> and <e20> drug2 </e20> is clinically warranted , an interval of at least # hours between the two drugs should be considered .
advise	coadministration of <e10> drug1 </e10> with <e20> drug2 </e20> is contraindicated .
advise	based on adult studies , an oral dose of <e10> drug1 </e10> of 2 . 5 mg twice daily is not recommended in patients receiving <e22> drug2 </e22> .
advise	therefore , co - administration of <e10> drug1 </e10> and <e22> drug2 </e22> is contraindicated .
advise	caution should be used when administering <e10> drug1 </e10> to patients receiving <e22> drug2 </e22> .
advise	tetracyclines : concomitant administration of <e10> drug1 </e10> and <e20> drug2 </e20> is contraindicated .
advise	appropriate laboratory testing of patients receiving <e10> drug1 </e10> with <e22> drug2 </e22> is recommended .
advise	particular caution is required when <e10> drug1 </e10> is administered concurrently with <e22> drug2 </e22> , since these agents have similar systemic effects .
advise	concomitant use of <e10> drug1 </e10> and other <e22> drug2 </e22> is not recommended .
advise	caution should be used when administering <e11> drug1 </e11> to patients taking <e20> drug2 </e20> .
advise	<e11> drug1 </e11> should not be administered concurrently with other <e22> drug2 </e22> ( e , g , , phenylephrine , dofetilide , digoxin , propranolol , etc ) or vasodilator _ drugs ( e , g , , epinephrine , norepinephrine , etc ) .
advise	if concomitant treatment with <e10> drug1 </e10> and <e20> drug2 </e20> is indicated , the drug1 dose should be reduced to half of the usual dose .
advise	if concomitant treatment with <e11> drug1 </e11> and an mao _ inhibitor ( e , g , , <e20> drug2 </e20> ) is clinically warranted , a careful titration of the two agents is advised .
advise	caution should be exercised if <e11> drug1 </e11> is co - administered with <e20> drug2 </e20> .
advise	drugs that should not be coadministered with <e11> drug1 </e11> antimycobacterial _ agents : amikacin , gentamicin , tobramycin , voriconazole , zalcitabine antimycobacterial _ agents : clarithromycin , indinavir antihistamines : <e20> drug2 </e20> antimycobacterial _ agents : rifampin antimycobacterial _ agents : rifabutin antimycobacterial _ agents : telithromycin
advise	quinolone _ antibiotic s : <e11> drug1 </e11> should not be used concomitantly with <e20> drug2 </e20> as drug2 is a potent serotoninergic _ agonist that can potentiate the effects of quinolone _ antibiotics ( particularly drug2 ) .
advise	it is recommended that , if concomitant treatment with <e10> drug1 </e10> and <e22> drug2 </e22> is clinically warranted , the patient be observed for at least # days before and # days after initiation of the new treatment regimen .
advise	consequently , concomitant administration of <e11> drug1 </e11> with strong cyp3a4 inhibitors such as ketoconazole , clarithromycin , ritonavir , <e20> drug2 </e20> , nelfinavir , ritonavir , drug2 , and indinavir is contraindicated .
advise	this interaction should be given consideration in patients taking <e10> drug1 </e10> concomitantly with <e20> drug2 </e20> .
advise	therefore , concurrent use of <e10> drug1 </e10> and <e22> drug2 </e22> is contraindicated .
advise	therefore , use of <e10> drug1 </e10> with <e20> drug2 </e20> is contraindicated .
advise	when concomitant administration of <e10> drug1 </e10> and <e20> drug2 </e20> is clinically necessary , dosage adjustments of the two agents may be necessary .
advise	caution should be used when administering <e10> drug1 </e10> to patients receiving or being treated with <e21> drug2 </e21> .
advise	this interaction should be given consideration in patients taking <e10> drug1 </e10> concomitantly with <e20> drug2 </e20> .
advise	concomitant administration of <e11> drug1 </e11> with <e22> drug2 </e22> should be avoided .
advise	however , because some patients may have suffered from hypertension before starting this drug , a close monitoring of the patient is recommended , as is the replacement of <e10> drug1 </e10> with <e22> drug2 </e22> .
advise	during concomitant therapy with <e11> drug1 </e11> and <e22> drug2 </e22> , hiv - 1 protease inhibitors ( pis ) should be titrated to ensure that their concentrations are in the desired range .
advise	dose adjustment of <e11> drug1 </e11> may be necessary when coadministered with agents that cross the blood - brain barrier ( e , g , , <e20> drug2 </e20> , phenytoin , phenobarbital ) .
advise	caution should be exercised when <e10> drug1 </e10> is administered with other <e22> drug2 </e22> .
advise	concomitant use of <e10> drug1 </e10> and <e20> drug2 </e20> is not recommended .
advise	if concomitant treatment with <e10> drug1 </e10> and <e20> drug2 </e20> is to be considered , patient dose should be reduced by 50 % and the drug1 dosage reduced by 30 % .
advise	therefore , co - administration of <e10> drug1 </e10> with <e20> drug2 </e20> is contraindicated .
advise	consequently , concomitant administration of <e10> drug1 </e10> with <e20> drug2 </e20> is contraindicated .
advise	<e10> drug1 </e10> should not be coadministered with other <e22> drug2 </e22> , including clarithromycin , amikacin , gentamicin , moxifloxacin , nefazadone , piperacillin _ 1 _ sodium , nefazadone _ sodium , norfloxacin , norfloxacin _ sodium , ergot _ alkaloids , ergotamine , methysergide , tobramycin , voriconazole , and voriconazole _ sodium .
advise	therefore , extreme caution should be used when administering <e10> drug1 </e10> to patients receiving <e20> drug2 </e20> or other antimicrobial agents that are primarily metabolized by this isoenzyme .
advise	therefore , co - administration of <e11> drug1 </e11> with other drugs that are metabolized by this isozyme ( e , g , , <e20> drug2 </e20> , clarithromycin , nefazadone , rifampin , nelfinavir ) should be approached with caution .
advise	therefore , such combined treatment with <e10> drug1 </e10> and <e20> drug2 </e20> should be avoided .
advise	however , careful attention should be paid to potential interactions when <e11> drug1 </e11> is used concomitantly with <e22> drug2 </e22> .
advise	drugs that should not be coadministered with <e11> drug1 </e11> antimigraine agents : <e20> drug2 </e20> : clonazepam , zolpidem , triazolam
advise	although a 3 - day course of <e10> drug1 </e10> has not been studied in patients receiving <e22> drug2 </e22> , such as aminoglycosides ( such as clarithromycin ) , it is suggested that such a course of treatment should be avoided .
advise	although the interactions observed in these studies are of only marginal clinical importance , caution should be exercised when <e10> drug1 </e10> is coadministered with other drugs of the central nervous system ( including <e20> drug2 </e20> , barbiturates , chlorpromazine , or thioridazine ) .
advise	therefore , the combination of <e10> drug1 </e10> with <e20> drug2 </e20> is contraindicated .
advise	brovana , as with other <e12> drug1 </e12> , should be given with caution to patients receiving <e21> drug2 </e21> .
advise	if concomitant treatment with <e10> drug1 </e10> and <e22> drug2 </e22> is clinically warranted , drug2 dosage should be reduced accordingly .
advise	<e10> drug1 </e10> should be given with caution to patients who have a history of treatment with other <e20> drug2 </e20> ( e , g , , paroxetine , fluoxetine , citalopram ) , because they may reduce the therapeutic response .
advise	coadministration of <e10> drug1 </e10> and <e20> drug2 </e20> is not recommended .
advise	caution should be exercised when administering <e10> drug1 </e10> with <e21> drug2 </e21> or other inhibitors of cyp3a4 , including those that inhibit monoamine oxidase ( mao ) a ( e , g , , nefazodone , fluvoxamine ) , mao - b ( e , g , , quinidine ) , or the indoleamine _ oxidase ( e , g , , nelfinavir ) .
advise	caution is advised when administering <e10> drug1 </e10> to patients who are receiving <e20> drug2 </e20> .
advise	nevertheless , caution is advised when administering <e10> drug1 </e10> with other <e20> drug2 </e20> ( e , g , , phenothiazines , carbamazepine , and triazolam ) .
advise	therefore , co - administration of <e10> drug1 </e10> and <e20> drug2 </e20> is contraindicated .
advise	serum drug2 levels should be monitored in patients receiving <e10> drug1 </e10> concomitantly with <e22> drug2 </e22> .
advise	dosage adjustment of <e10> drug1 </e10> may be necessary when coadministered with <e22> drug2 </e22> .
advise	if concomitant treatment with <e11> drug1 </e11> and <e20> drug2 </e20> is clinically warranted , patients should be observed for treatment response and dosage adjustment is advised .
advise	therefore , co - administration of <e11> drug1 </e11> with other potent cyp3a4 inhibitors ( e , g , , <e20> drug2 </e20> , nafazodone , sirolimus , flecainide , telithromycin , and itraconazole ) should be approached with caution .
advise	therefore , co - administration of <e10> drug1 </e10> with other <e20> drug2 </e20> is not recommended .
advise	this interaction should be given consideration in patients taking <e10> drug1 </e10> concomitantly with <e21> drug2 </e21> .
advise	therefore concomitant administration of <e10> drug1 </e10> and <e22> drug2 </e22> is contraindicated .
advise	consequently , concomitant administration of <e10> drug1 </e10> and <e20> drug2 </e20> is not recommended .
advise	dose adjustment of <e10> drug1 </e10> may be required when co - administered with <e20> drug2 </e20> .
advise	methotrexate : caution should be exercised if <e10> drug1 </e10> is administered concomitantly with <e22> drug2 </e22> .
advise	therefore , co - administration of <e11> drug1 </e11> with drugs that are metabolized by this isozyme , including certain antidepressants ( tricyclic _ antidepressants [ tcas ] , such as nortriptyline [ <e20> drug2 </e20> ] , fluoxetine [ fluoxetine ] and imipramine [ imipramine ] ) , dopamine _ agonists ( such as nefazadone [ next ] and risperidone [ risper ] ) , serotonin _ agonists ( such as citalopram [ citocita ] and quinidine [ quinoline ] ) and type _ 1c _ antiarrhythmics ( such as propafenone [ profane ] and flecainide [ flunaflower ] , should be approached with caution ) should be approached with caution .
advise	therefore , # to # mg oral <e10> drug1 </e10> doses should be reduced to # mg in patients receiving <e22> drug2 </e22> .
advise	concomitant administration of <e10> drug1 </e10> and <e22> drug2 </e22> is not recommended .
advise	consequently , concomitant administration of <e10> drug1 </e10> and other antidepressants ( tricyclic _ antidepressants [ tcas ] , such as nortriptyline [ <e21> drug2 </e21> ] , imipramine [ isrix ] , or paroxetine [ purify ] ) is contraindicated .
advise	at least # weeks of treatment with <e10> drug1 </e10> should be administered before initiating <e21> drug2 </e21> .
advise	<e10> drug1 </e10> should not be administered concomitantly with agents that are metabolized by cyp3a4 , including certain antidepressants , <e20> drug2 </e20> , type _ 1c _ antiarrhythmics ( e , g , , propafenone , flecainide ) , type _ 2c _ antiarrhythmics ( e , g , , propafenone ) , type _ 1c _ antiarrhythmics ( e , g , , encainide ) , type _ 2c _ antiarrhythmics ( e , g , , quinidine ) , type _ 1c _ antihistamines ( e , g , , dezocine ) , type _ 2c _ antihistamines ( e , g , , sotalol ) , or theophylline .
advise	therefore , co - administration of <e10> drug1 </e10> with other drugs that are extensively metabolized by this isoenzyme ( e , g , , ketoconazole , itraconazole , clarithromycin , nefazodone , <e20> drug2 </e20> , ritonavir , nefazadone , nelfinavir ) should be approached with caution .
advise	close supervision and careful adjustment of the dosage are required when <e11> drug1 </e11> is administered with <e20> drug2 </e20> .
advise	before taking <e10> drug1 </e10> , tell your doctor if you are taking any of the following medicines : - aspirin or another salicylate such as magnesium / choline _ salicylate ( trilisate ) ; - <e20> drug2 </e20> ( optilizer ) ; - magnesium _ salicylate ( trilisate ) ; or - magnesium _ choline _ salicylate ( optilizer ) .
advise	consequently , concomitant administration of <e10> drug1 </e10> with other drugs that are metabolized by this isozyme , including certain antidepressants , opioids , carbamazepine , and <e20> drug2 </e20> ( e , g , , propafenone , flecainide , and encainide ) , should be approached with caution .
advise	at least # days should elapse between the first <e10> drug1 </e10> dose and the first <e22> drug2 </e22> .
advise	<e10> drug1 </e10> should not be used with drugs known to prolong the qt interval , including drugs that prolong the heart rate ( e , g , , <e20> drug2 </e20> ) , antidepressants ( e , g , , nortriptyline ) , dopamine _ hydrogen _ guanidine ( e , g , , quinidine ) , atropine , phenothiazines ( e , g , , diltiazem ) , amiodarone , and triazolam .
advise	therefore , when <e10> drug1 </e10> is co - administered with <e22> drug2 </e22> ( such as phenothiazines and triazolam ) , benzodiazepine dosage should be reduced to a minimum .
advise	based on the clinical experience , the concomitant use of <e11> drug1 </e11> with <e20> drug2 </e20> is not recommended .
advise	antacids : enteric - coated <e12> drug1 </e12> are not recommended for use with <e22> drug2 </e22> .
advise	caution should be used when <e10> drug1 </e10> is administered concomitantly with <e20> drug2 </e20> or other potent inhibitors of cyp3a ( e , g , , ketoconazole , nefazodone , indinavir , ritonavir , saquinavir , telithromycin ) .
advise	therefore concomitant administration of <e11> drug1 </e11> with other drugs that may enhance cyp3a4 activity ( e , g , , ketoconazole , itraconazole , clarithromycin , <e20> drug2 </e20> , ritonavir ) should be undertaken with caution .
advise	because of the potential for an additive effect , co - administration of <e10> drug1 </e10> with other drugs that have a significant peripheral α - blocker effect ( e , g , , ketoconazole , itraconazole , ritonavir , <e20> drug2 </e20> , nefazodone , telithromycin , ritonavir ) should be approached with caution .
advise	drug1 : <e12> drug1 </e12> should not be used with the following <e22> drug2 </e22> : heparin , fibrinogen , or warfarin .
advise	although the clinical significance of this effect is not known , the dose of <e10> drug1 </e10> should be carefully monitored when using <e20> drug1 </e20> as a sole bronchodilator .
advise	caution is advised when administering <e11> drug1 </e11> with other <e20> drug2 </e20> .
advise	coadministration of <e10> drug1 </e10> and antidepressants ( <e20> drug2 </e20> , fluoxetine , sertraline ) should be approached with caution , and concomitant treatment with these agents should be undertaken only with extreme caution .
advise	if the <e11> drug1 </e11> dose is reduced , adjustment of the <e22> drug2 </e22> dose should be considered .
advise	dosage adjustment of <e10> drug1 </e10> is recommended when coadministered with <e20> drug2 </e20> .
advise	therefore , co - administration of <e11> drug1 </e11> with other drugs that are extensively metabolized by this isozyme ( e , g , , cyclosporine , tacrolimus , indinavir , ritonavir , <e20> drug2 </e20> , etc ) is not recommended .
advise	before taking <e10> drug1 </e10> , tell your doctor if you are taking any of the following medicines : - lithium - phenytoin - <e22> drug2 </e22> - diuretics - beta - blockers - amiodarone - indinavir - saquinavir - ritonavir - emtricitabine - saquinavir
advise	concomitant administration of <e10> drug1 </e10> and <e20> drug2 </e20> is not recommended .
advise	if concomitant treatment with <e10> drug1 </e10> and <e20> drug2 </e20> is to be achieved , the two agents should not be administered in the same patient .
advise	concomitant use of <e10> drug1 </e10> and <e22> drug2 </e22> is not recommended .
advise	this interaction should be given consideration in patients taking <e11> drug1 </e11> concurrently with <e20> drug2 </e20> .
advise	considerable caution should be used when <e10> drug1 </e10> is administered to patients receiving other <e22> drug2 </e22> or beta - blocker agents .
advise	it is recommended to not exceed a single # mg oral <e10> drug1 </e10> dose in patients receiving <e20> drug2 </e20> .
advise	however , due to the nature of the interaction , co - administration of <e11> drug1 </e11> with drugs that are extensively metabolized by this isoenzyme ( e , g , , <e20> drug2 </e20> , thioridazine , or ritonavir ) should be approached with caution .
advise	nonetheless , individual patients should be advised to avoid the concomitant use of <e10> drug1 </e10> and <e20> drug2 </e20> .
advise	<e11> drug1 </e11> should not be used with other drugs that may potentiate platelet aggregation , including intravenous methylprednisolone , phenytoin , <e20> drug2 </e20> , and type _ 1c _ antiarrhythmics ( e , g , , propafenone , flecainide , norethindrone ) .
advise	<e10> drug1 </e10> should be used cautiously in patients who are taking <e20> drug2 </e20> or other strong cyp3a4 inhibitors .
advise	if treatment with <e10> drug1 </e10> is initiated in a patient being treated with <e20> drug2 </e20> , drug2 should not be started until the drug has been discontinued .
advise	coadministration of <e10> drug1 </e10> with drugs that affect dopamine function ( e , g , , <e20> drug2 </e20> , maois , and phenothiazines ) should be undertaken with caution .
advise	if additional <e12> drug1 </e12> are needed after the # dose of <e21> drug2 </e21> has been administered , the anticoagulant dose should be reduced to the # minimum effective dose ( # mg ) .
advise	coadministration of <e10> drug1 </e10> and <e20> drug2 </e20> should be approached with caution .
advise	therefore , co - administration of <e11> drug1 </e11> with other <e22> drug2 </e22> is not recommended .
advise	the concomitant use of <e10> drug1 </e10> and <e20> drug2 </e20> is not recommended .
advise	a dose increase in <e10> drug1 </e10> to 5 mg daily may be necessary when coadministered with <e20> drug2 </e20> .
advise	thus , concomitant administration of <e11> drug1 </e11> with <e20> drug2 </e20> should be avoided .
advise	caution should be exercised when administering <e10> drug1 </e10> to patients receiving <e22> drug2 </e22> therapy .
advise	therefore , co - administration of <e10> drug1 </e10> with other <e22> drug2 </e22> is contraindicated and should be approached with caution .
advise	<e10> drug1 </e10> should be administered with caution to patients taking <e22> drug2 </e22> or erythromycin .
advise	however , caution should be used when <e10> drug1 </e10> is co - administered with <e20> drug2 </e20> as ergotamine is metabolized by cyp2d6 .
advise	therefore , co - administration of <e10> drug1 </e10> and other antidepressants ( <e20> drug2 </e20> , haloperidol , paroxetine , sertraline , citalopram , fluoxetine , desipramine , sertraline , fluvoxamine , fluvoxamine ) should be approached with caution .
advise	therefore , co - administration of <e10> drug1 </e10> and <e20> drug2 </e20> is contraindicated .
advise	caution should be used when administering <e11> drug1 </e11> to patients receiving <e22> drug2 </e22> .
advise	therefore , co - administration of <e10> drug1 </e10> and certain <e22> drug2 </e22> is contraindicated .
advise	nafazodone , fluvoxamine , cimetidine , <e10> drug1 </e10> , nortriptyline , fluvoxamine _ d3 , diltiazem , indinavir , and ritonavir ( alts ) should not be used in combination with <e21> drug2 </e21> because of possible additive and potentiating effects .
advise	considerable caution should be exercised when administering <e10> drug1 </e10> with any of the <e22> drug2 </e22> .
advise	therefore , when <e11> drug1 </e11> is given with other <e22> drug2 </e22> , the anesthetic dosage should be reduced or discontinued if possible .
advise	in case of the patient taking <e10> drug1 </e10> concurrently with <e20> drug2 </e20> , the dose of drug1 should be reduced from 1 mg twice daily to 0 . 25 mg twice daily .
advise	drugs that lower ca2 + level : caution should be used when <e10> drug1 </e10> is given with <e22> drug2 </e22> , since the effect of drug1 on the cardiac output is similar to that of the angiotensin - converting enzyme inhibitor and the ace - inhibitor .
advise	based on these findings , when <e10> drug1 </e10> is used with other <e22> drug2 </e22> agents , it is recommended that an interval of at least # hours be given between the two drug2 doses .
advise	dosage adjustment of <e11> drug1 </e11> is not required if <e22> drug2 </e22> is given concurrently .
